antaranusa.com | berita nusantara internasional

Helm Expands into Australia with Presence in Sydney

Wed, 04 Nov 2026 21:23:00 +0700

International private markets technology and infrastructure company establishes local presence to support wealth firms, asset managers and ecosystem firms across Australia and New Zealand.

NEW YORK AND SYDNEY, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Helm, the international private markets operating system backed by iAltA, today announced it has expanded into Sydney to support its growth across Australia and New Zealand.

The expansion establishes a local presence for Helm as product manufacturers, wealth firms and service providers across the region increasingly seek more efficient ways to structure, distribute and manage private market investments. James Wilkinson, former General Manager at iPartners, will lead Helm in the region.

Private markets are continuing to grow in scale across asset classes, investment structures and distribution channels, creating new opportunities for end investors but adding complexity for the firms that serve them. In Australia and New Zealand, that evolution is increasing the need for enterprise-grade infrastructure that can connect historically fragmented processes and point solutions across the investment lifecycle.

"Australia has developed a sophisticated and rapidly evolving private markets ecosystem, and we see a significant opportunity to support those firms that are broadening access to private markets," said Gareth Lewis, Chief Business Officer of Helm. "Establishing a local presence allows us to work more closely with clients and partners in the region and bring technology and expertise that can help them manage the increasing complexity of private market investing."

Helm helps private market participants reduce that complexity by connecting product and distribution with investor onboarding, transaction workflows and reporting. Its configurable technology is designed to help firms build.

The expansion to Sydney will give Helm an on-the-ground presence to work with clients and partners and build relationships across the Australian and New Zealand private markets ecosystem.

"Australia and New Zealand represent an exciting opportunity for Helm because of both the maturity of the wealth channel and the growing advisor and investor interest in private markets," Wilkinson said. "Having a team on the ground means we can combine Helm's global capabilities with a real understanding of how firms here operate, what their clients expect and simplify their processes to operate more efficiently so they can focus on what they do best."

About Helm

Backed by iAltA, Helm is a private markets operating system that helps product manufacturers and investment firms simplify capital raising and investor workflows. Supporting a range of use cases, Helm is designed to reduce operational friction and improve the delivery of private market offerings to investors. Visit www.helmmarkets.com

About iAltA

Launched in 2025 by founding partners Scott Ganeles, Bill Sherman, Bill Crager, and Laurence Tosi, iAltA is a holding company founded by experienced operators to address systemic gaps in private markets infrastructure. Incubated and backed by WestCap, iAltA builds platforms that unify fragmented workflows, elevate transparency, and empower product manufacturers and investment firms throughout the investment lifecycle. Visit www.ialta.com

Iveco Group 2026 Third Quarter Results

Wed, 04 Nov 2026 21:17:00 +0700

A quarter marked by continued efforts in quality initiatives,

with revenue growth offset by a temporary product mix impact

Following the successful completion of the tender offer,

Iveco Group is now part of Tata Motors

EU-IFRS FINANCIAL MEASURES					NON-EU-IFRS FINANCIAL MEASURES ⁽¹⁾
	(EUR million)	Q3 2026	Q3 2025	Change		(EUR million)	Q3 2026	Q3 2025	Change
	Consolidated EBIT	11	91	-80		Adjusted EBIT	30	111	-81
	of which EBIT of Industrial Activities	(18)	56	-74		of which Adjusted EBIT of Industrial Activities	-	76	-76
	Profit/(loss) for the period	(45)	16	-61		Adjusted Net Income (Loss)	(32)	40	-72
	Diluted EPS EUR	(0.17)	0.06	-0.23		Adjusted Diluted EPS EUR	(0.12)	0.15	-0.27
	Cash flow from operating activities	(113)	102	-215		Free Cash Flow of Industrial Activities	(656)	(513)	-143
	Cash and cash equivalents⁽²⁾	1,786	2,514	-728		Available Liquidity⁽²⁾	3,713	4,432	-719

In the third quarter, Iveco Group recorded consolidated revenues of EUR3.16 billion, an increase of 1.4%, and Industrial Activities net revenues of EUR3.09 billion (+1.5%). Industrial Activities Adjusted EBIT was nil, mainly on the back of continued focus on quality, as planned, negative product mix and inflation impact. Free Cash Flow registered an outflow of EUR656 million, in line with seasonality typical of this quarter, while Available Liquidity remained solid at EUR3.7 billion as of 30th September 2026, including EUR1.9 billion of undrawn committed facilities.

Truck confirmed its leadership position in the chassis cab segments and further reinforced it in the upper end of the light commercial vehicle (LCV) market. Compared to the third quarter of 2025, European industry volumes were largely stable across all ranges. European order intake in medium - and heavy-duty remained solid, increasing 23% and remained broadly flat in light-duty. While profitability was affected by competitive pressure in LCV, driven by flattish industry demand, the business unit maintained disciplined pricing in European heavy-duty vehicles.

IVECO BUS confirmed its place among the leaders in the European e-bus market and consolidated its strong market share in the City and Intercity segments. Due to the unfavorable comparison to the same quarter of 2025, when Intercity demand peaked, deliveries fell 6%. Profitability was also affected by a negative product mix.

In Powertrain, overall engine volumes increased by 5% compared to the third quarter of 2025, due to a steady increase in European small-engine deliveries across off- and on-road applications. Fewer large-engine deliveries, particularly in the Americas, affected profitability; an impact that was partially offset by disciplined cost control and continued operational efficiencies. Continuous efforts in quality initiatives, as planned, have negatively affected third quarter's profitability across business units.

Looking ahead, despite weaker industry demand for LCVs, macroeconomic uncertainties, a negative product mix and continuous effort in quality initiatives across business, the Company expects profitability to recover in Q4 2026. Industrial Activities free cash flow generation is expected to be solid in the last quarter of the year, as per usual seasonality.

"In the third quarter, we continued to prioritise quality throughout the company, dedicating additional resources in line with the strategy we set for the year. This deliberate choice weighed on profitability, along with an unfavourable product mix across business units. Our efforts in quality reached their peak during the quarter and, from now onwards, will gradually decrease. Their benefits will become increasingly visible in our performance and will eventually make a positive contribution to our results. Overall, our revenues were slightly up versus the previous year, demonstrating the solid competitiveness of our products."

Olof Persson, Chief Executive Officer

Notes:

Iveco Group consolidated financial results included in this press release are prepared in accordance with EU-IFRS.

(*) 2026 and 2025 financial data shown in this press release refer to Continuing Operations only (ie. excluding Defence business), unless otherwise stated. In particular, on 18th March 2026, Iveco Group transferred the full ownership of its Defence business (IDV and ASTRA brands) to Leonardo S.p.A., as per the terms of the agreement announced on 30th July 2025. In accordance with IFRS 5 - Non-current Assets Held for Sale and Discontinued Operations, as the sale became highly probable in July 2025, the Defence business met the criteria to be classified as a disposal group held for sale since that date; it also met the criteria to be classified as Discontinued Operations.

(1) Non-EU-IFRS financial measures: refer to the "Non-EU-IFRS Financial Information" section of this press release for information regarding non-EU-IFRS financial measures. Refer to the specific table in the "Other Supplemental Financial Information" section of this press release for the reconciliation between the non-EU-IFRS financial measure and the most comparable EU-IFRS financial measure.

(2) Comparison vs 30th June 2026.

Q3 2026 Performance and Results by Business Unit

Consolidated revenues amounted to EUR3,158 million compared to EUR3,115 million in Q3 2025, up 1.4%. Net revenues of Industrial Activities were EUR3,091 million compared to EUR3,044 million in Q3 2025, up 1.5%, mainly due to higher volumes in Europe and favourable foreign exchange impacts, partially offset by lower pricing.

Adjusted EBIT was EUR30 million compared to EUR111 million in Q3 2025, with a margin of 0.9% (3.6% in Q3 2025). Adjusted EBIT of Industrial Activities was nil compared to EUR76 million in Q3 2025, mainly due to unfavourable production costs due to strengthened quality focus, Truck net pricing, and negative product mix across businesses.

Adjusted Net Loss was EUR32 million (Adjusted Net Income of EUR40 million in Q3 2025) and Adjusted Diluted Earnings per share was negative EUR0.12 (positive EUR0.15 in Q3 2025).

Net financial expenses amounted to EUR72 million compared to EUR58 million in Q3 2025, mainly due to a negative impact of hyperinflation accounting in T?rkiye and higher borrowing costs.

Reported income tax was EUR16 million, with an Adjusted Effective Tax Rate (Adjusted ETR(1)) of 24% in Q3 2026, which reflects the different tax rates applied in the jurisdictions where the Group operates and some discrete items.

Free Cash Flow of Industrial Activities was negative at EUR656 million compared to negative EUR513 million in Q3 2025, mainly due to working capital absorption and higher investments.

Available Liquidity was EUR3,713 million as of 30th September 2026, including EUR1,900 million of undrawn committed facilities.

Truck

	Q3 2026	Q3 2025	Change		The European Truck market was down 2% year-over-year, with Light-Duty Vehicles (LCV) down 4% and Medium- and Heavy-Duty Trucks (M&H) in line with Q3 2025. The South American Truck market was aligned with the previous year. Iveco Group deliveries were up 12% vs Q3 2025 in Europe (up 9% and 22% in LCV and M&H, respectively) and were up 4% in South America (up 31% in LCV and down 13% in M&H). Worldwide Truck book-to-bill was 0.94 at the end of the quarter. Net Revenues were EUR 2,099 million, up 4.5% compared to Q3 2025, mainly driven by higher volumes. The Adjusted EBIT was EUR 10 million compared to EUR 59 million in Q3 2025, primarily driven by negative product mix and net pricing, as well as strengthened focus on quality. The Adjusted EBIT margin was at 0.5% (2.9% in Q3 2025).
Net revenues (EUR million)	2,099	2,008	+4.5%
Adjusted EBIT (EUR million)	10	59	-49
Adjusted EBIT margin	0.5%	2.9%	-240	bps

Notes:

Bus

	Q3 2026	Q3 2025	Change		Bus registrations were down 1% in Europe and were flat in South America compared to Q3 2025. Iveco Group deliveries were down 7% and 5% in Europe and South America, respectively. Net Revenues were down 5.6% in the quarter, driven by lower volumes and mix. The Adjusted EBIT was EUR 5 million compared to EUR 29 million in Q3 2025, resulting from negative product mix and continuous quality initiatives. The Adjusted EBIT margin was at 0.7% (4.0% in Q3 2025).
Net revenues (EUR million)	679	719	-5.6%
EUR djusted EBIT (EUR million)	5	29	-24
Adjusted EBIT margin	0.7%	4.0%	-330	bps

Powertrain

	Q3 2026	Q3 2025	Change		Powertrain Net Revenues were ?810 million, up 8.7% compared to Q3 2025, due to higher small-engine deliveries. Sales to external customers accounted for 48% (49% in Q3 2025). The Adjusted EBIT was EUR 24 million compared to EUR 38 million in Q3 2025, primarily driven by negative product mix and higher product costs for increased resources dedicated to quality. The Adjusted EBIT margin was at 3.0% (5.1% in Q3 2025).
Net revenues ( million)	810	745	+8.7%
EUR djusted EBIT (EUR million)	24	38	-14
Adjusted EBIT margin	3.0%	5.1%	-210	bps

Financial Services

	Q3 2026	Q3 2025	Change	Financial Services Net Revenues were EUR 110 million, in line with Q3 2025. The Adjusted EBIT was at EUR 30 million compared to EUR 35 million in Q3 2025, due to deteriorated collection performances. The end of period managed portfolio for Iveco Group (including unconsolidated joint ventures) was EUR 7,846 million at the end of the quarter (of which retail was 43% and wholesale 57%), up EUR 316 million compared to 30^thSeptember 2025. The receivable balance greater than 30 days past due as a percentage of the on-book portfolio was 2.6% (2.1% as of 30^thSeptember 2025).
Net revenues (EUR million)	110	111	-0.9%
Adjusted EBIT (EUR million)	30	35	-5
Equity at quarter end (EUR million)	806	830	-24
Retail loan originations (EUR million)	421	389	+32

Iveco Group Results for the Nine Months ended 30^th September 2026

EU-IFRS FINANCIAL MEASURES					NON EU-IFRS FINANCIAL MEASURES⁽¹⁾
	(EUR million)	Q3 YTD 2026	Q3 YTD 2025	Change		(EUR million)	Q3 YTD 2026	Q3 YTD 2025	Change
	Consolidated EBIT	23	314	-291		Adjusted EBIT	106	399	-293
	of which EBIT of Industrial Activities	(68)	216	-284		of which Adjusted EBIT of Industrial Activities	14	301	-287
	Profit/(loss) for the period	(123)	109	-232		Adjusted Net Income/(Loss)	(60)	179	-239
	Diluted EPS EUR	(0.47)	0.40	-0.87		Adjusted diluted EPS EUR	(0.23)	0.66	-0.89
	Cash flow from operating activities	(352)	(3)	-349		Free Cash Flow of Industrial Activities	(1,382)	(1,241)	-141
	Cash and cash equivalents⁽²⁾	1,786	2,953	-1,167		Available Liquidity⁽²⁾	3,713	5,192	-1,479

Truck

	Q3 YTD 2026	Q3 YTD 2025	Change
Net revenues (EUR million)	6,352	6,317	+0.6%
Adjusted EBIT (EUR million)	13	246	-233
Adjusted EBIT margin	0.2%	3.9%	-370	bps

Bus

	Q3 YTD 2026	Q3 YTD 2025	Change
Net revenues (EUR million)	2,214	1,948	+13.7%
Adjusted EBIT (EUR million)	35	97	-62
Adjusted EBIT margin	1.6%	5.0%	-340	bps

Powertrain

	Q3 YTD 2026	Q3 YTD 2025	Change
Net revenues (EUR million)	2,541	2,407	+5.6%
Adjusted EBIT (EUR million)	85	115	-30
Adjusted EBIT margin	3.3%	4.8%	-150	bps

Financial Services

	Q3 YTD 2026	Q3 YTD 2025	Change
Net revenues (EUR million)	322	338	-4.7%
Adjusted EBIT (EUR million)	92	98	-6

Notes:

(2) Comparison vs 31st December 2025.

Non-EU-IFRS Financial Information

Iveco Group monitors its operations through the use of several non-EU-IFRS financial measures including Adjusted EBIT, Adjusted EBIT margin, Adjusted Net Income/(Loss), Adjusted Diluted EPS, Adjusted Income Taxes, Adjusted Effective Tax Rate, Free Cash Flow of Industrial Activities, Net Cash (Debt) and Net Cash (Debt) of Industrial Activities, and Available Liquidity. Iveco Group's management believes those measures provide useful and relevant information regarding Iveco Group's operating results and enhance the readers' ability to assess Iveco Group's financial performance and financial position. Management uses these non-EU-IFRS financial measures to monitor the underlying performance of Iveco Group's business and operations, to identify operational trends, as well as to make decisions regarding future spending, resource allocations and other operational decisions as they provide additional transparency with respect to Iveco Group's core operations. These non-EU-IFRS financial measures have no standardised meaning under EU-IFRS and are unlikely to be comparable to other similarly titled measures used by other companies and are not intended to be substitutes for measures of financial performance and financial position as prepared in accordance with EU-IFRS. Iveco Group's non-EU-IFRS financial measures are defined as follows:

Adjusted EBIT: is defined as EBIT before restructuring costs and non-recurring items, if any. In particular, non-recurring items are specifically disclosed items that management considers rare or discrete events that are infrequent in nature and not reflective of ongoing operational activities. The performance of Iveco Group is reviewed based on the Adjusted EBIT, which the management believes more fully reflects Iveco Group's profitability, and, as such, Iveco Group uses Adjusted EBIT for internal reporting to assess performance as part of the forecasting, budgeting and decision-making process as it provides additional transparency regarding Iveco Group's underlying operating performance. The management believes Adjusted EBIT is useful because it excludes items that management believes are not indicative of Iveco Group's underlying operating performance between periods. The management also believes that Adjusted EBIT is useful for investors and analysts to better understand how management assesses Iveco Group's underlying operating performance on a consistent basis. Accordingly, Iveco Group believes that Adjusted EBIT provides useful information to third party stakeholders in understanding and evaluating Group's operations;

Adjusted EBIT margin; is computed by dividing a) Adjusted EBIT by b) Net revenues;

Adjusted Net Income/(Loss): is defined as profit/(loss) for the period, before restructuring costs and non-recurring items, if any, net of the related income tax effect. In particular, non-recurring items are specifically disclosed items that management considers rare or discrete events that are infrequent in nature and not reflective of ongoing operational activities. Iveco Group uses Adjusted Net Income/(Loss) to assess performance as part of its decision-making process as it provides additional insight into Iveco Group's underlying overall performance, net of income tax. The management believes that Adjusted Net Income/(Loss) is also useful for investors and analysts to better understand how management assesses Iveco Group's underlying overall performance on a consistent basis. Accordingly, Iveco Group believes that Adjusted Net Income/(Loss) provides useful information to third party stakeholders in understanding and evaluating Group's operations;

Adjusted Diluted EPS: is computed by dividing Adjusted Net Income/(Loss) attributable to Iveco Group N.V. by a weighted-average number of Common Shares outstanding during the period that takes into consideration potential Common Shares outstanding deriving from the Iveco Group share-based payment awards, when inclusion is not anti-dilutive. When Iveco Group provides guidance for adjusted diluted EPS, the Group does not provide guidance on an earnings per share basis because the EU-IFRS measure will include potentially significant items that have not yet occurred and are difficult to predict with reasonable certainty prior to year-end;

Adjusted Income Taxes: is defined as income taxes less the tax effect of restructuring expenses and non-recurring items, and non-recurring tax charges or benefits;

Adjusted Effective Tax Rate (Adjusted ETR): is computed by dividing a) Adjusted Income Tax (expense) benefit by b) Adjusted Profit/(Loss) before taxes. Adjusted Income Tax (expense) benefit represents income tax (expense) benefit, adjusted for the income tax (expense) benefit of restructuring costs and non-recurring items, if any, as well as any non-recurring tax expenses or benefits. Adjusted Profit/(Loss) before taxes represents profit/(loss) before taxes of the applicable period, adjusted for restructuring costs and non-recurring items, if any. Adjusted ETR fully reflects Iveco Group's level of taxation, based on Group's Profit/(Loss) before taxes, removing extraordinary and non-recurring items. The management believes that this is useful for investors and analysts to better understand Iveco Group's level of taxation on a consistent basis and enables them to compare Iveco Group's level of taxation with that of other companies;

Free Cash Flow of Industrial Activities (or Industrial Free Cash Flow): refers to Industrial Activities, only, and is computed as consolidated cash flow from operating activities less: cash flow from operating activities of Financial Services; investments of Industrial Activities in property, plant and equipment and intangible assets; as well as other changes and intersegment eliminations. Iveco Group views Free Cash Flow as a useful measure for measuring its cash generation ability;

Net Cash (Debt) and Net Cash (Debt) of Industrial Activities: Net Cash (Debt) is defined as total Debt (including debt payable to CNH deriving from financing activities and sale of trade receivables) plus Derivative liabilities, net of Cash and cash equivalents, Derivative assets and other current financial assets (primarily current securities, short-term deposits and investments towards high-credit rating counterparties) and financial receivables from CNH deriving from financing activities and sale of trade receivables. Iveco Group provides the reconciliation of Net Cash (Debt) to Total (Debt), which is the most directly comparable EU-IFRS financial measure included in the Group's Consolidated Statement of Financial Position. Due to different sources of cash flows used for the repayment of the debt between Industrial Activities and Financial Services (by cash from operations for Industrial Activities and by collection of financing receivables for Financial Services), management separately evaluates the cash flow performance of Industrial Activities using Net Cash (Debt) of Industrial Activities; and

Available Liquidity: is defined as cash and cash equivalents, including restricted cash, undrawn medium-term unsecured committed facilities, other current financial assets (primarily current securities, short-term deposits and investments towards high-credit rating counterparties), and financial receivables from CNH deriving from financing activities and sale of trade receivables.

Forward-looking statements

Statements other than statements of historical fact contained in this earning release, including competitive strengths; business strategy; future financial position or operating results; budgets; projections with respect to revenue, income, earnings (or loss) per share, capital expenditures, dividends, liquidity, capital structure or other financial items; costs; and plans and objectives of management regarding operations and products, are forward-looking statements. These statements may include terminology such as "may", "will", "expect", "could", "should", "intend", "estimate", "anticipate", "believe", "outlook", "continue", "remain", "on track", "design", "target", "objective", "goal", "forecast", "projection", "prospects", "plan", or similar terminology. Forward-looking statements are not guarantees of future performance. Rather, they are based on current views and assumptions and involve known and unknown risks, uncertainties and other factors, many of which are difficult to predict and/or are outside the Company's control. If any of these risks and uncertainties materialise (or they occur with a degree of severity that the Company is unable to predict) or other assumptions underlying any of the forward-looking statements prove to be incorrect, including any assumptions regarding strategic plans, the actual results or developments may differ materially from any future results or developments expressed or implied by the forward-looking statements. Factors, risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements include, among others: the continued uncertainties related to the unknown duration and economic, operational and financial impacts of ongoing and/or threatened international conflicts and geopolitical tensions; vulnerability to cybersecurity or data privacy incidents, also due to potential massive availability of Generative Artificial Intelligence; the many interrelated factors that affect consumer confidence and worldwide demand for capital goods and capital goods-related products, including demand uncertainty caused by current macroeconomic and geopolitical issues; changes in government policies regarding banking, monetary and fiscal policy; legislation, particularly pertaining to capital goods-related issues such as the environment, debt relief and subsidy program policies, trade and commerce and infrastructure development; government policies on international trade and investment, including sanctions, import quotas, capital controls and tariffs; volatility in international trade caused by the imposition of tariffs, sanctions, embargoes, and trade wars; actions of competitors in the various industries in which we compete; development and use of new technologies and technological difficulties; the interpretation of, or adoption of new, compliance requirements with respect to engine emissions, safety or other aspects of our products; production difficulties, including capacity and excess inventory levels; labour relations; interest rates and currency exchange rates; inflation and deflation; energy prices; our ability to obtain financing or to refinance existing debt; price pressure on new and used vehicles; the resolution of pending litigation and investigations on a wide range of topics, including dealer and supplier litigation, follow-on private litigation in various jurisdictions after the settlement of the EU antitrust investigation of the Iveco Group announced on 19 July 2016, intellectual property rights disputes, product warranty and defective product claims, and emissions and/or fuel economy regulatory and contractual issues; security breaches, cybersecurity attacks, technology failures, and other disruptions to the information technology infrastructure of Iveco Group and its suppliers and dealers; security breaches with respect to our products; further developments of geopolitical threats which could impact our operations, supply chains, distribution network, as well as negative evolutions of the economic and financial conditions at global and regional levels; political and civil unrest; volatility and deterioration of capital and financial markets, including other pandemics, terrorist attacks or acts of war in Europe and elsewhere; our ability to realise the anticipated benefits from our business initiatives as part of our strategic plan; our failure to realise, or a delay in realising, all of the anticipated benefits of our acquisitions, joint ventures, strategic alliances or divestitures and other similar risks and uncertainties, and our success in managing the risks involved in the foregoing.

Forward-looking statements are based upon assumptions relating to the factors described in this earnings release, which are sometimes based upon estimates and data received from third parties. Such estimates and data are often revised. Actual results may differ materially from the forward-looking statements as a result of a number of risks and uncertainties, many of which are outside Iveco Group's control. Except as otherwise required by applicable rules, Iveco Group expressly disclaims any intention to provide, update or revise any forward-looking statements in this announcement to reflect any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. Further information concerning Iveco Group, including factors that potentially could materially affect Iveco Group's financial results, is included in Iveco Group's reports and public filings under applicable regulations.

About Iveco Group

Iveco Group N.V. (EXM: IVG) is a global player in the automotive industry, built on a strong Italian heritage and with a consolidated international reach. The Group channels decades of engineering excellence and innovation into sustainable mobility and customer driven technologies. Its five brands play a leading role in their respective domains: IVECO, a pioneering commercial vehicles brand offering heavy, medium and light duty trucks; FPT, a global leader in advanced powertrain technologies in the agriculture, construction, marine, power generation and commercial vehicles sectors; IVECO BUS and HEULIEZ, renowned for their mass transit, premium bus and coach solutions; and IVECO CAPITAL, the Group's financing arm supporting them all. Iveco Group employs 33,000 people and operates 16 industrial sites and 22 R&D centres. Further information is available on the Company's website www.ivecogroup.com.

UPDATE -- Hotel101 Global Enters Egypt - Its First Entry in the African Continent

Wed, 04 Nov 2026 20:36:00 +0700

SINGAPORE, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hotel101 Global Holdings Corp. (NASDAQ Ticker: HBNB) ("Hotel101" or "Hotel101 Global"), a leading asset-light, prop-tech hospitality platform pioneering a globally standardized "condotel" business model, listed on the Nasdaq Stock Exchange and a subsidiary of Philippine-listed DoubleDragon Corporation (PSE Ticker: DD), announces the signing of definitive binding agreements for a country-wide joint venture for the expansion of Hotel101 in Egypt, starting with the development of an approximately 750-room Hotel101 in Cairo, Egypt.

This expansion marks a significant milestone in the company's global growth strategy, bringing its novel, globally standardized condotel business model to one of the Middle East and Africa's most dynamic capital cities and a major cultural tourism gateway.

The country-wide joint venture for the expansion of Hotel101 into Egypt is between Hotel101 Global Pte. Ltd. and IGI Holding's affiliates, WNTR Property and WNTR Hospitality. The Sheta family has built and led Egypt's IGI Group since 1942. Over successive generations, the group has grown into a diversified enterprise with interests spanning textiles, FMCG, food and beverage, heavy industry, petroleum, construction, hospitality and real estate. Building on this foundation, IGI is now expanding into new sectors, with investments in industrial minerals and digital infrastructure. IGI Developments, the group's real-estate arm, has been a pioneer of integrated residential compounds in Egypt since the mid-1990s. Over more than 30 years it has delivered multiple integrated communities; it holds a land portfolio of up to approximately 2.5 million square meters in strategic locations and currently houses more than 40,000 residents.

The hotel, to be named Hotel101-Cairo West, is planned to occupy a prime site in Hay Al Ashgar along Ahmed Zewail Road in 6th of October City, Giza. This strategic position is expected to offer guests connectivity via major arterial roads, including El Wahat Road and the Cairo Ring Road, with access to Sphinx International Airport and the wider Greater Cairo road network. The area has rapidly emerged as one of West Cairo's key growth districts, known for its modern infrastructure, improving transport links, and strong mix of residential, commercial, and tourism developments, while sitting within the broader catchment of the Giza Pyramids and the Grand Egyptian Museum.

Key Location Advantages:

* Prime Ahmed Zewail Road Position: Located along Ahmed Zewail Road with direct access to El Wahat Road and links to the Cairo Ring Road. Upon completion, guests are expected to benefit from road connectivity and proximity to Sphinx International Airport, providing access for both domestic and international travelers.

* Proximity to Major Attractions: Situated within the West Cairo corridor serving the Giza Pyramids and Grand Egyptian Museum. The site is expected to offer a balance of modern urban development and cultural tourism demand, with easy access to key attractions, residential communities, and commercial amenities across Greater Cairo.

When completed, Hotel101-Cairo West is expected to generate a total project value of approximately 5.465 billion Egyptian Pounds (US$102.09 million) and is expected to be completed by 2029, forming part of Hotel101 Global's global expansion strategy.

Hotel101-Cairo West is expected to offer 4-star amenities at affordable prices, including a ballroom, ample meeting spaces, and a conference center tailored for business events. Consistent with Hotel101's offerings across its locations globally, guests are expected to enjoy modern rooms, 24/7 reception, all-day dining, swimming pools, a full-size gym, a business center, children's playground, ample parking, luggage storage, and other amenities.

The development is subject to customary governmental, regulatory, corporate and other approvals.

About Hotel101 Global

Listed on Nasdaq (Ticker: HBNB) with a market capitalization of approximately US$1.1 billion as of October 16, 2026, Hotel101 is an asset-light, prop-tech hospitality platform pioneering a globally standardized "condotel" business model. Hotel101 aims to disrupt the global hotel and hospitality sector through its unique tech-enabled business model that positions it to generate revenues twice: first from the advance sale of individual hotel units during the construction phase; and second, from long-term recurring revenue derived from day-to-day hotel operations. The expansion of Hotel101 toward its long-term goal to operate in 100 countries globally is expected to be driven mainly by joint ventures and, in the future, license agreements with local developers in various countries worldwide.

The Hotel101 Global Group is advancing its global expansion plans toward its medium-term goal to be in 25 countries and its long-term goal of operating one million Hotel101 rooms in 100 countries globally.

Forward-Looking Statements

This document includes certain "forward-looking statements" within the meaning of securities laws of certain jurisdictions, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this document, including statements regarding the future financial position, business strategy, plans and objectives of management for future operations of Hotel101 Global Holdings Corp. ("HBNB") and its subsidiaries (the "HBNB Group"), are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "set," "expect," "predict," "potential" or the negative of these terms or other similar expressions. Forward-looking statements include, without limitation, HBNB's expectations concerning anticipated sales revenue once fully sold and project value, the project location, expected number of rooms, expected project completion date and expansion goals, the outlook for the HBNB Group's business, productivity, plans and goals for future operational improvements and capital investments, operational performance, future market conditions or economic performance and developments in the capital and credit markets and expected future financial performance, as well as any information concerning possible or assumed future results of operations of the HBNB Group.

These forward-looking statements are based on the beliefs and assumptions of the management of HBNB. Although HBNB believes that such plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, HBNB cannot assure you that such plans, intentions or expectations will be achieved or realized. Forward-looking statements involve a number of risks, uncertainties and assumptions and actual results or events may differ materially from those projected or implied in those statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the HBNB Group's ability to execute on its business model, potential business expansion opportunities in foreign countries and growth strategies, manage future growth, retain and expand customers' use of its hotel services and attract new customers, and source and maintain talent; risks relating to joint venture partners, including owners of pre-sold condotel units in Hotel101 hospitality projects, who may have interests different from and may take actions that adversely affect the HBNB Group; risks relating to project cost and completion; risks relating to the HBNB Group's sources of cash and cash resources; risks relating to offering deferred payment schemes, including the risk of customer default; the HBNB Group's ability to effectively compete in the highly competitive hospitality industry; any declines or disruptions in the travel and hospitality industries or economic downturn; applicable laws and regulations to real estate development and marketing activities and hotel operation and management activities in the jurisdictions where the HBNB Group has operations or intends to expand into; and other risks and uncertainties discussed in HBNB's annual report for the year ended December 31, 2025 on Form 20-F and under the heading "Risk Factors" in HBNB's registration statement on Form F-4 (File No.: 333-287130) and other documents to be filed by HBNB from time to time with the U.S. Securities and Exchange Commission.

The foregoing list of factors is not exhaustive. Should one or more of these risks or uncertainties materialize, or should any of HBNB's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that are not presently known to HBNB or that HBNB currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements.

HBNB cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date hereof. Forward-looking statements set forth herein speak only as of the date of this document. HBNB does not undertake any obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs. In the event that any forward-looking statement is updated, no inference should be made that HBNB will make additional updates with respect to that statement, related matters or any other forward-looking statements.

Ondine Capital Announces First Close of Fund III to Drive AI and Semiconductor Innovation

Wed, 04 Nov 2026 07:36:00 +0700

Ondine Capital's newly appointed partner: Brian Yen

Source: Ondine Capital

TAIPEI, TAIWAN - Media OutReach Newswire - 3 November 2026 - Ondine Capital today announced the successful first close of its third USD-denominated VC fund. Ondine Capital Fund III has secured commitments from top-tier institutional and strategic limited partners, including several leading semiconductor enterprises in Taiwan.

Building on the firm's deep-rooted expertise in semiconductors and deep technology, Ondine Capital Fund III will invest across the full AI value chain-spanning AI foundation models, next-generation semiconductors, AI infrastructure, AI-native software, and physical AI applications.

Ondine Capital Fund III's early portfolio highlights include:

*Recursive Superintelligence: Founded by former Salesforce Chief Scientist Richard Socher and built by veteran researchers from OpenAI, Google, and Meta, the startup focuses on recursive self-improving AI systems. It recently raised $650 million at a $4 billion pre-money valuation led by Google Ventures, with participation from Nvidia and AMD.

*Bot Auto: Founded by Xiaodi Hou (former co-founder and CTO of TuSimple), this Houston-based physical AI startup specializes in autonomous freight transportation. Bot Auto recently partnered with Ryan Transportation to launch driverless freight operations along the Houston-Dallas corridor.

*Salience Labs: Founded by Vaysh Kewada and Johannes Feldmann, the company develops silicon-photonics optical switching technology for AI data centers. Partnering with Tower Semiconductor, Salience Labs recently closed a $125 million financing round led by Bullhound Capital, with strategic backing from AMD Ventures and Intel Capital.

Partner Appointment to Boost Global Ecosystem

Coinciding with the first close, Ondine Capital announced the appointment of Brian Yen as Partner, reinforcing the firm's global sourcing and founder network.

Prior to joining Ondine Capital, Brian Yen served as Principal and Head of the Taipei Office at Headline Asia, where he cultivated an extensive network across Japan, Taiwan, and Southeast Asia. His investment track record spans consumer technologies, agentic services, and physical AI, with notable investments including respond.io, forest inc., Braid, and iMotorbike. At Ondine Capital, Brian Yen will focus on backing early-stage founders building intelligent software and physical AI platforms.

"The convergence of AI and semiconductors is unleashing unprecedented opportunities across global tech," said Brian Yen. "As these technologies mature, we anticipate monumental value creation throughout the entire stack. Through Fund III, we look forward to empowering visionary founders who are shaping the future of computing and industry applications."

Ondine Capital continues to actively deploy capital and evaluate global investment opportunities in breakthrough, category-defining companies across the AI and semiconductor landscape.

About Ondine Capital

Ondine Capital is a premier venture capital firm focused on frontier technologies, including semiconductors, artificial intelligence, enterprise software, clean energy, and emerging technology platforms. The firm backs visionary founders from inception, providing strategic support and access to a robust global network of industrial partners, investors, and entrepreneurs.

The issuer is solely responsible for the content of this announcement.

Hashtags: #OndineCapital #RSI #BotAuto #SalienceLabs

https://www.ondinecap.com/

2026 Tropical Rainforest Ecosystem Partners Conference: Global Gathering to Protect Earth's Green Lungs

Wed, 04 Nov 2026 07:29:00 +0700

Photo: A Hainan Gibbon (Nomascus hainanus) photographed in the Bawangling Area of the National Park of Hainan Tropical Rainforest

Source: The Organizing Committee of 2026 Tropical Rainforest Ecosystem Partners Conference

HAIKOU, CHINA - Media OutReach Newswire - 3 November 2026 - From Nov. 18 to 22, 2026, a global gathering dedicated to protecting the Earth's "green lungs" will take place in Haikou, Hainan Province, China: the 2026 Tropical Rainforest Ecosystem Partners Conference.

From the vast Amazon rainforest to the dense forests of the Congo Basin and the diverse landscapes of the Malay Archipelago, representative rainforests from around the world will come together with the National Park of Hainan Tropical Rainforest for dialogue and exchange. Under the theme "Global Treasures ? Shared Future," the conference embodies humanity's shared commitment to protecting rainforests and pursuing sustainable development.

Tropical rainforests cover less than one-tenth of the Earth's land area, yet they are home to more than half of the world's plant and animal species. Hainan, China's only tropical island province, is home to the country's largest, most concentrated and best-preserved contiguous tropical rainforest on a continental island. Established in 2021, the National Park of Hainan Tropical Rainforest covers more than 4,269 square kilometers and protects over 95 percent of Hainan Island's primary forests. Its forest coverage rate remains stable at 95.9 percent, while both its water and air quality excellence rates stand at 100 percent.

Over the past five years, this rainforest has continued to witness remarkable ecological achievements. The Hainan gibbon population has grown to 44 individuals across seven groups, making it the only gibbon population in the world to have shown sustained growth.

In addition, 91 previously undocumented wild plant and animal species have been recorded in the park. An integrated space-air-ground ecological monitoring system now provides round-the-clock, comprehensive monitoring and protection of the rainforest ecosystem. The "Bawangling Model" for Hainan gibbon conservation has also been recognized by the International Union for Conservation of Nature (IUCN) as a global model for protecting rare species.

The conference will explore how forests can serve as reservoirs of water, sources of food, generators of economic value and carbon sinks. Two keynote forums and four parallel forums will be held, bringing together participants for in-depth discussions on key topics, including water conservation and aquatic ecological security, the sustainable use of forest food resources, ways to unlock the value of ecological products, and carbon management in rainforests. The discussions will foster exchanges of ideas and the sharing of experience.

The conference will also focus on Hainan's efforts to seek dual World Heritage recognition for its natural and cultural heritage. It will bring together global expertise to support the nomination of the Hainan Tropical Rainforest and the Traditional Settlement of Li Ethnic Group for inscription on the UNESCO World Heritage List as a mixed natural and cultural heritage property. The initiative will explore new approaches to rainforest governance that uphold ecological protection as a firm priority while bringing tangible benefits to local communities.

In addition to the conference sessions, a series of supporting events will be held. "Rainforest Night," a showcase of Hainan's intangible cultural heritage, will offer an immersive audiovisual experience showcasing the distinctive traditions of the Li and Miao ethnic groups. The "Hidden Realms ? Shared Life" Hainan Tropical Rainforest Photography Exhibition and the "Gifts of Nature" Ecological Products Market will showcase the rainforest's natural beauty and innovative ways of turning ecological resources into tangible benefits. Field expeditions into the Hainan Tropical Rainforest, media tours, and the public-interest initiative "Breathe Deep in the Rainforest ? Protect Our Shared Habitat" will take participants deep into the rainforest to experience the vitality of its ecosystems.

As the Hainan Free Trade Port approaches the first anniversary of the launch of island-wide special customs operations and the National Park of Hainan Tropical Rainforest marks its fifth anniversary, this conference will serve as China's green calling card to the world and provide a platform for international dialogue and cooperation on rainforest conservation.

The issuer is solely responsible for the content of this announcement.

Acronis Appoints HoJin Kim as Chief Revenue Officer

Wed, 04 Nov 2026 07:24:00 +0700

Acronis Appoints HoJin Kim as Chief Revenue Officer

Veteran channel executive brings more than 25 years of experience to accelerate global revenue growth and strengthen Acronis' MSP partner ecosystem

SCHAFFHAUSEN, Switzerland, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Acronis, a global provider of an AI-native cyber platform for MSPs and IT departments, today announced the appointment of HoJin Kim as Chief Revenue Officer (CRO).

In this role, HoJin will lead Acronis' global sales and go-to-market organization, with a focus on accelerating revenue growth, strengthening partner relationships, and expanding opportunities for managed service providers (MSPs) worldwide.

"HoJin's extensive channel expertise and proven ability to drive growth through partner ecosystems make him a strong addition to our leadership team," said Prakash Panjwani, CEO of Acronis. "As we continue to expand our global footprint and strengthen our position in the MSP market, his experience in scaling sales organizations, deepening partner engagement, and driving cybersecurity adoption will be instrumental in accelerating our next phase of growth."

HoJin brings more than 25 years of experience leading global and regional IT channel organizations, with deep expertise in cybersecurity, partner strategy, and driving growth through the channel. His appointment reinforces Acronis' commitment to its partner-first strategy and to building a scalable, high-performing global sales organization.

Most recently, HoJin served as Chief Revenue Officer at WatchGuard Technologies, where he led the company's global sales and channel organization. During his tenure, he focused on expanding the adoption of endpoint detection and response (EDR) and managed detection and response (MDR) services across MSPs, while driving network security sales and encouraging partners to leverage WatchGuard's Unified Security Platform.

"I'm excited to join Acronis and work with a company that puts partners and customers at the center of its strategy," said HoJin Kim. "Acronis has a compelling opportunity to help MSPs grow their businesses while enabling corporate customers to address increasingly complex cybersecurity and data protection challenges. I look forward to working with the global team to expand market opportunities, strengthen execution, and drive long-term growth across both our partner and corporate businesses."

Prior to WatchGuard, HoJin served as Chief Revenue Officer at The Channel Company, where he was responsible for driving revenue growth and executing the company's long-term strategy. He previously held senior global channel leadership positions at SonicWall, Samsung, and Hewlett Packard Enterprise, as well as regional partner management roles at Juniper Networks and IBM. Throughout his career, HoJin has developed and executed channel strategies designed to strengthen partner relationships, expand market reach, and deliver sustainable business growth.

About Acronis

Acronis is a leader in AI-native cyber protection, unifying data protection, cybersecurity, IT operations and hybrid infrastructure to deliver business continuity, security and compliance with less cost and complexity. More than 21,000 service providers trust Acronis to protect over 750,000 businesses in 150 countries. Acronis is headquartered in Schaffhausen, Switzerland. For more information, visit www.acronis.com.

Univar Solutions Completes Acquisition of Lavo Bulk Business in Canada

Wed, 04 Nov 2026 07:16:00 +0700

Transaction strengthens company's presence in Eastern Canada and expands complementary chemical solutions and capabilities for customers

DOWNERS GROVE, Ill., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Univar Solutions LLC ("Univar Solutions" or "the Company"), a leading global solutions provider to users of specialty ingredients and chemicals, today announced that it has completed the acquisition of the certain assets of KIK Consumer Products' Lavo Bulk business in Canada ("Lavo Bulk").

The acquisition strengthens Univar Solutions' presence in Eastern Canada and expands the complementary chemical solutions and capabilities the Company can provide to customers in the region.

"The addition of Lavo Bulk is a strong strategic fit with our business and our commitment to growing with key customers and critical suppliers in Canada," said Bob Craycraft, Chief Executive Officer, Chemical Distribution & Services for Univar Solutions. "We are pleased to welcome the Lavo Bulk team to Univar Solutions. Together, we look forward to building on their established expertise, relationships and capabilities while continuing to deliver the safe, reliable service our customers expect."

The Lavo Bulk leadership and sales team dedicated to the Lavo Bulk business have joined Univar Solutions, helping preserve established expertise, customer and supplier relationships, and knowledge of the business' operational and supply requirements.

"We see meaningful opportunities to build on the strength of the business and deepen our relationships with customers and supplier partners across the region," added Chris Halberg, Senior Regional Vice President, Canada and EMEA, Chemical Distribution & Services for Univar Solutions. "Our immediate focus is on a smooth transition, supporting our new colleagues and maintaining the high level of service customers have come to expect."

About Univar Solutions

Univar Solutions is a leading global specialty chemical and ingredient distributor representing a premier portfolio from the world's leading producers. With one of the industry's largest private transportation fleets and technical sales force, unparalleled logistics know-how, deep market and regulatory knowledge, formulation and recipe development, and leading digital tools, the Company is well-positioned to offer tailored solutions and value-added services to a wide range of markets, industries, and applications. While fulfilling its purpose to help keep communities healthy, fed, clean, and safe, Univar Solutions is committed to helping customers and suppliers innovate and focus on Growing Together. Learn more at univarsolutions.com.

Forward-Looking Statements

This communication contains "forward-looking statements" under applicable law regarding financial and operating items relating to the Company's business. Forward-looking statements generally can be identified by words such as "believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates," "anticipates" or other comparable terms. All forward-looking statements made in this communication are qualified by this cautionary language.

Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond the Company's control, that could result in expectations not being realized or could otherwise materially and adversely affect the Company's business, financial condition, results of operations or cash flows. Although the forward-looking statements are based on what management believes to be reasonable assumptions, we caution you that the forward-looking information presented in this communication is not a guarantee of future events or results, and that actual events or results may differ materially from those made in or suggested by the forward-looking information contained in this communication.

For additional information regarding factors that could affect the Company, please see the Company's most recent annual report and other financial reports, including the information set forth under the caption "Risk Factors." Any forward-looking statements represent the Company's views only as of the date of this communication and should not be relied upon as representing the Company's views as of any subsequent date, and the Company undertakes no obligation, other than as may be required by law, to update any forward-looking statement.

Univar Solutions Merampungkan Akuisisi Bisnis Lavo Bulk di Kanada

Wed, 04 Nov 2026 07:12:00 +0700

Transaksi ini memperkuat kehadiran perusahaan di Kanada Timur serta memperluas solusi kimia pelengkap serta kapabilitas perusahaan bagi pelanggan

DOWNERS GROVE, Ill.,, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Univar Solutions LLC ("Univar Solutions" atau "Perusahaan"), penyedia solusi global terkemuka bagi pengguna bahan baku dan bahan kimia khusus, hari ini mengumumkan bahwa pihaknya telah merampungkan akuisisi atas sejumlah aset tertentu dari bisnis Lavo Bulk milik KIK Consumer Products di Kanada ("Lavo Bulk").

Akuisisi ini memperkuat kehadiran Univar Solutions di Kanada Timur serta memperluas solusi kimia pelengkap serta kapabilitas yang dapat ditawarkan Perusahaan kepada pelanggan di wilayah tersebut.

"Penambahan Lavo Bulk sangat selaras dengan strategi bisnis kami serta komitmen kami untuk terus bertumbuh bersama pelanggan utama dan pemasok penting di Kanada," ujar Bob Craycraft, Chief Executive Officer, divisi Chemical Distribution & Services di Univar Solutions. "Kami dengan senang hati menyambut bergabungnya tim Lavo Bulk ke Univar Solutions. Bersama-sama, kami berharap dapat terus mengembangkan keahlian, hubungan, dan kapabilitas yang telah mereka bangun, sekaligus terus memberikan layanan yang aman dan andal sesuai dengan yang diharapkan pelanggan kami."

Jajaran pimpinan dan tim penjualan Lavo Bulk yang secara khusus menangani bisnis Lavo Bulk telah bergabung dengan Univar Solutions. Langkah ini membantu mempertahankan keahlian yang telah dimiliki, hubungan dengan pelanggan dan pemasok, serta pengetahuan mengenai kebutuhan operasional dan pasokan bisnis tersebut.

"Kami melihat peluang besar untuk mengembangkan lebih lanjut keunggulan bisnis ini dan mempererat hubungan dengan pelanggan serta mitra pemasok di seluruh wilayah tersebut," tambah Chris Halberg, Senior Regional Vice President untuk Kanada dan EMEA pada divisi Chemical Distribution & Services di Univar Solutions. "Fokus utama kami saat ini adalah memastikan kelancaran proses transisi, yang mendukung rekan-rekan baru kami, serta mempertahankan standar layanan tinggi yang selama ini diharapkan pelanggan."

Tentang Univar Solutions

Univar Solutions merupakan distributor global terkemuka untuk bahan baku dan bahan kimia khusus, yang mewakili portofolio produk unggulan dari berbagai produsen terkemuka dunia. Didukung oleh salah satu armada transportasi milik sendiri dan tim penjualan teknis terbesar di industri, keahlian teknis tentang logistik yang tak tertandingi, pengetahuan mendalam tentang pasar dan regulasi, kemampuan pengembangan formulasi dan resep, serta perangkat digital terdepan, Perusahaan memiliki posisi kuat untuk menawarkan solusi khusus dan layanan bernilai tambah untuk berbagai pasar, industri, dan aplikasi.

Dalam mewujudkan tujuannya untuk membantu menjaga masyarakat tetap sehat, terpenuhi kebutuhan pangannya, bersih, dan aman, Univar Solutions berkomitmen membantu pelanggan dan pemasok berinovasi serta berfokus pada semangat Tumbuh Bersama. Pelajari lebih lanjut di univarsolutions.com.

Pernyataan Berwawasan ke Depan

Komunikasi ini memuat "pernyataan berwawasan ke depan" berdasarkan hukum yang berlaku tentang aspek keuangan dan operasional yang terkait dengan bisnis Perusahaan. Pernyataan berwawasan ke depan umumnya dapat dikenali dari penggunaan kata-kata seperti "meyakini," "memperkirakan," "mungkin," "akan," "seharusnya," "dapat," "berupaya," "bermaksud," "berencana," "mengestimasi," "mengantisipasi," atau istilah lainnya yang sebanding. Seluruh pernyataan berwawasan depan yang disampaikan dalam komunikasi ini dibatasi oleh pernyataan kehati-hatian ini.

Pernyataan berwawasan ke depan mengandung berbagai risiko dan ketidakpastian yang diketahui maupun tidak diketahui, yang sebagian besar mungkin berada di luar kendali Perusahaan, yang dapat menyebabkan ekspektasi tidak tercapai atau dapat berdampak secara signifikan dan merugikan terhadap bisnis, kondisi keuangan, hasil operasi, atau arus kas Perusahaan.

Meskipun pernyataan berwawasan ke depan didasarkan pada asumsi yang dianggap wajar oleh manajemen, kami mengingatkan bahwa informasi berwawasan ke depan yang disajikan dalam komunikasi ini bukan merupakan jaminan atas peristiwa atau hasil di masa mendatang, dan bahwa peristiwa atau hasil aktual dapat berbeda secara signifikan dari hal-hal yang dinyatakan secara tersurat maupun tersirat oleh informasi berwawasan ke depan yang dimuat dalam komunikasi ini.

Untuk informasi tambahan mengenai faktor-faktor yang dapat memengaruhi Perusahaan, silakan lihat laporan tahunan terbaru Perusahaan dan laporan keuangan lainnya, termasuk informasi yang tercantum dalam bagian berjudul "Faktor Risiko."

Setiap pernyataan berwawasan ke depan hanya mencerminkan pandangan Perusahaan pada tanggal komunikasi ini dan tidak boleh dianggap sebagai menggambarkan pandangan Perusahaan pada tanggal setelahnya dan Perusahaan tidak berkewajiban untuk memperbarui pernyataan berwawasan ke depan apa pun, kecuali sebagaimana diwajibkan oleh hukum.

Bitget Records $1.86 Trillion in Q3 Trading Volume, Expands Liquidity Across Crypto and TradFi

Wed, 04 Nov 2026 07:08:00 +0700

VICTORIA, Seychelles, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Bitget, the world's largest Universal Exchange (UEX), has released its Q3 2026 Transparency Report, recording $1.86 trillion in combined trading volume as trading activity grew across crypto derivatives, spot markets, and traditional financial products, supported by deeper liquidity and expanded cross-asset trading capabilities.

Trading activity scaled across every major category during the quarter, with combined monthly volume rising 21.2% from July to September. Crypto derivatives grew 31.5% to $409.19 billion, crypto spot volume rose 65.7%, and CFD trading expanded 39.7% to contribute $376.32 billion for the quarter, now the platform's largest non-crypto category.

That growth was supported by deepening liquidity. That direction took a concrete step forward with the launch of Bitget's Cross-Asset Unified Account (UTA), bringing more than 370 eligible assets, including 100+ tokenized US stocks, into a shared margin framework with collateral valuation ratios of up to 95%. The upgrade allows eligible tokenized equities to be used as collateral across different trading products, giving users more flexibility in managing their capital.

Bitget also expanded its AI-powered trading tools, extending GetAgent Playbook to tokenized US equities. Other developments included institutional pricing upgrades and the introduction of Cash Plus, a yield-generating stablecoin product.

"We're seeing more traders move between crypto, stocks and traditional assets, and that's why we are building a Universal Exchange," said Gracy Chen, CEO of Bitget. "Q3 showed strong growth, but it also reminded us that protecting our users must continue to remain our biggest priority as we expand."

Independent research also highlighted Bitget's liquidity performance. TokenInsight ranked Bitget first among nine exchanges for combined BTC and ETH futures depth within 0.05% of market price, recording $41.6 million in liquidity. CoinGecko identified Bitget among the leading exchanges for BTC and ETH spot liquidity. In tokenized equities, CryptoRank found Bitget's Reality recorded up to 58% lower simulated slippage on $50,000 orders than the next-lowest comparable venue, while DeFiLlama reported a median bid-ask spread of 0.83 basis points and the deepest top-of-book liquidity across five markets evaluated.

Following the September 24 security incident, Bitget implemented containment and recovery measures, with users account balances remaining unaffected. The company engaged Mandiant and SlowMist to support an independent investigation and replenished its Protection Fund to more than $300 million by September 30, ahead of its original commitment. Bitget also continued strengthening its security infrastructure by introducing a circuit breaker mechanism, passing an independent SlowMist assessment, and increasing its security budget, while maintaining a Proof of Reserves ratio above 110%.

About Bitget

Bitget is the world's largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 500+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution.

Bitget is driving crypto adoption through strategic partnerships such as MotoGP. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry's lowest fees and highest liquidity across 150 regions worldwide.

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose.

The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered.

Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

GBA Science Forum 2026 Held Across Guangdong, Hong Kong, and Macao: Driving Collaborative Innovation to Build a Global Sci-Tech Hub

Wed, 04 Nov 2026 06:59:00 +0700

Scene from the Opening Ceremony of the 2026 Greater Bay Area Science Forum

Source: Guangdong Lingshan Forum Science Center

GUANGZHOU, CHINA - Media OutReach Newswire - 3 November 2026 - Co-hosted across Guangdong, Hong Kong, and Macao from October 31 to November 2, the 2026 Greater Bay Area (GBA) Science Forum took place with a strong focus on future industries and cutting-edge technologies.

Jointly guided by the Ministry of Science and Technology and the Chinese Academy of Sciences (CAS), this year's event highlights national strategic leadership to accelerate the implementation of key policies and technological breakthroughs in the region.

The forum features an opening ceremony, a main forum, 15 specialized sub-forums, and 10 signature events. While the opening ceremony and main forum were held on November 1 in Nansha, Guangzhou, parallel sessions are rolling out across Hong Kong, Shenzhen, Huizhou, Dongguan, and Yangjiang, demonstrating a deeply integrated and synergistic approach to the event across multiple cities.

The opening ceremony witnessed the release of new support measures for the GBA International Sci-Tech Innovation Center, jointly introduced by relevant state ministries and central authorities. A key highlight is the commitment to fortifying the region's original innovation capacity by supporting the development of a world-class cluster of major sci-tech infrastructures in the GBA. Furthermore, two national key R&D projects under the 15th Five-Year Plan, spearheaded by Guangdong Province, were officially launched: the "Advanced Biotherapeutic Technologies Project" and the "GBA International Sci-Tech Innovation Center Project."

The ceremony also featured the signing of the Guangdong-Hong Kong-Macao Collaborative Innovation Joint Funding Program, as well as major sci-tech cooperation agreements between CAS and Guangdong Province, marking another solid step in translating national strategic visions into concrete actions.

Since its inception in December 2021, the GBA Science Forum has been successfully held for five editions. It has evolved into a premier high-level exchange platform and a vital showcase for the matchmaking and achievements of the GBA International Sci-Tech Innovation Center.

This year's forum brought together four Nobel laureates, alongside distinguished academicians from home and abroad, young scientists, and leading tech entrepreneurs.

Together, they shared their latest research findings and visionary insights on critical topics, including cutting-edge scientific breakthroughs, future technological trends, and the deep integration of scientific and industrial innovation.

In recent years, the GBA International Sci-Tech Innovation Center has demonstrated robust innovation momentum and cultivated a thriving developmental environment. This vitality was globally recognized in September 2026, when the World Intellectual Property Organization (WIPO) published its Global Innovation Index 2026 Top 100 Science and Technology Clusters, with the "Shenzhen-Hong Kong-Guangzhou" cluster securing the number one spot globally once again.

The issuer is solely responsible for the content of this announcement.

Teva's Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO, AJOVY and UZEDY; Delivers Substantial Gross Margin Expansion

Tue, 03 Nov 2026 22:54:00 +0700

COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA LAUNCH AND STRATEGIC ADDITION OF BXCL-501

Q3 2026 revenues of $4.4 billion, a decrease of 2% year-over-year in both U.S. dollars and local currency terms, reflecting lower global generics revenues, primarily due to increased competition for lenalidomide capsules (a generic version of Revlimid) in the U.S. This decrease was partially offset by continued strong growth across Teva's key innovative brands.

Strong profitability: Gross profit margin was 55.5% in the third quarter of 2026, compared to 51.4% in the third quarter of 2025; non-GAAP gross profit margin increased to the highest quarterly level in the last decade, by 345 basis points to 58.7%, excluding the $500 million development milestone payments received for duvakitug (anti-TL1A) in Q4 2025; operating income was $714 million and non-GAAP operating income was $1,393 million; diluted earnings per share (EPS) was $0.20 and non-GAAP diluted EPS was $0.86; cash flow generated from operating activities was $241 million and free cash flow was approximately $0.5 billion.

Key innovative brands continued to drive Teva's portfolio transformation, collectively generating approximately $1.1 billion in revenues and growing 33% year-over-year in local currency:

AUSTEDO global revenues were $751 million, increasing 21% year-over-year in local currency. Teva is raising its 2026 revenue outlook to $2.55 billion-$2.65 billion, from $2.45 billion-$2.60 billion.

AJOVY global revenues were $269 million, increasing 61% year-over-year in local currency. Teva is raising its 2026 revenue outlook to $930 million-$960 million, from $850 million-$870 million.

UZEDY revenues were $85 million, increasing 96% year-over-year in local currency. Teva is raising its 2026 revenue outlook to $290 million?$310 million, from $270 million-$290 million.

Building the next wave of neuroscience growth: Teva received FDA approval for WELTRUZA in the U.S. in October 2026, marking a significant expansion for long-acting injectable schizophrenia treatment and highlighting Teva's established commercial capabilities and deep understanding of the patient journey. The Company continues to target LAI schizophrenia portfolio (UZEDY and WELTRUZA) with peak sales potential of $1.5 billion-$2.0 billion.

Expanding Teva's growth through strategic business development:

Acquired BXCL-501, from BioXcel Therapeutics Inc., which is under FDA review for potential at-home use for the acute treatment agitation associated with schizophrenia or bipolar I or II disorder in adults;

Deepened collaboration with Samsung Bioepis for the commercialization of two additional biosimilars, infliximab-abda, a biosimilar to Remicade? (infliximab), and etanercept-ykro, a biosimilar to Enbrel (etanercept), expanding the Company's burgeoning global pipeline and portfolio of biosimilars.

Generics and biosimilars remain an important foundation: global generics revenues decreased 16% year-over-year in local currency, primarily reflecting lower U.S. revenues from lenalidomide capsules (a generic version of Revlimid), partially offset by recently launched generic products and growth in biosimilars. Teva's biosimilars business continued to expand and is currently expected to exceed $0.8 billion in 2026 revenues, achieving our original 2027 revenue objective one year ahead of plan.

Innovative pipeline successes strengthen Teva's longer-term growth profile with the potential to launch at least one product per year over five years:

The U.S. FDA accepted the ecopipam New Drug Application (NDA) for review, advancing a potential first-in-class selective D1 receptor anti-agonist for Tourette syndrome in the pediatric population, with an action date expected in Q1 2027.

Teva reported positive Phase 2a results for anti-IL-15 (TEV-駰) in Celiac disease, and is targeting to begin Phase 2b in vitiligo in Q4 2026.

Teva discontinued its phase 2 Multiple System Atrophy (MSA) study of emrusolmin (TEV-饶), following an interim futility analysis that indicated low probability of the study meeting its primary efficacy endpoint if continued.

Financial strength, with continued value creation for shareholders: the return to an investment grade credit rating, refinancing of ~$4.9 billion in debt during Q3 2026, and the direct listing of Teva's ordinary shares on the New York Stock Exchange (NYSE); all reflect Teva's strong execution of its Pivot to Growth strategy, continued financial strength and long-term shareholder value creation.

Finalized Most-Favored-Nation (MFN) agreement with the U.S. Administration, including a prospective pricing commitment with respect to certain future innovative product launches.

Q3 2026 Highlights:

Revenues of $4.4 billion (-2% YoY)

GAAP diluted EPS of $0.20 (-47% YoY); non-GAAP diluted EPS of $0.86 (+10% YoY) includes $0.02 of acquired IPR&D charges

GAAP net income of $233 million; Adjusted EBITDA of $1.5 billion (+7% YoY)

Cash flow generated from operating activities of $241 million; Free cash flow of $495 million (-4% YoY)

GAAP gross profit margin of 55.5%; non-GAAP gross profit margin of 58.7%, an increase of 345 basis points year-over-year, the highest quarterly level in the last decade when excluding the $500 million development milestone payments received for duvakitug (anti-TL1A) in Q4 2025

2026 Business Outlook - Innovative brand revenues outlook increased, non-GAAP operating income outlook increased for underlying operational performance, offset by increased IPR&D*:

Revenues: $16.7-$17.0 billion

Non-GAAP operating income: $3.8-$3.9 billion; includes $0.87 billion of acquired IPR&D charges

Adjusted EBITDA: $4.23-$4.43 billion; includes $0.87 billion of acquired IPR&D charges

Non-GAAP diluted EPS: $1.92$-2.11; includes $0.71 of acquired IPR&D charges

Free cash flow: $2.1-$2.4 billion

AUSTEDO revenues: $2.55 billion-$2.65 billion

AJOVY revenues: $930 million-$960 million

UZEDY revenues: $290 million-$310 million

*IPR&D impact is presented due to uncertainty of the future occurrence and timing of these transactions

TEL AVIV, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2026.

Richard Francis, Teva's President and CEO, said: "Our strong third-quarter performance is another clear demonstration of Pivot to Growth in action and how far Teva has come. The FDA approval of WELTRUZA has further advanced our innovative portfolio, our recently announced biosimilars agreement with Samsung Bioepis has strengthened our generics powerhouse and our return to investment grade reflects the transformation of our financial position. Together, these achievements represent how we are delivering sustained innovative growth and translating that growth into greater profitability, with our three key innovative brands collectively growing 33% in local currency to approximately $1.1 billion year-over-year. This performance, together with continued margin expansion and cash flow generation, gives us the confidence to raise our 2026 revenue outlook for all three brands."

Mr. Francis added: "At the same time, we are continuously building the next phase of sustainable growth at Teva. The U.S. launch of WELTRUZA expands our schizophrenia franchise, while progress across ecopipam, anti-IL-15 and our broader late-stage pipeline supports our ambition to deliver at least five potential innovative launches over five years. Our return to investment grade and debt refinancing reflect our strengthened financial position."

Pivot to Growth Strategy

In the third quarter of 2026 and into October 2026, Teva continued to execute on the four pillars of its Pivot to Growth strategy:

Delivering on our growth engines

Teva's key innovative brands, AUSTEDO, AJOVY and UZEDY, collectively generated approximately $1.1 billion in revenues and grew 33% year-over-year in local currency. Strong performance across all three brands supports increased 2026 revenue outlooks of these products and continues to shift Teva's portfolio toward innovative medicines. The FDA approval and U.S. launch of WELTRUZA further expand Teva's long-acting injectable schizophrenia portfolio and builds on the commercial momentum established by UZEDY.

Stepping up innovation

Teva continued to advance a differentiated late-stage pipeline across neuroscience and immunology. The FDA accepted ecopipam's (EBS-101) NDA for review, positive Phase 2a results were reported for anti-IL-15 (TEV-駰) in Celiac disease, and the anti-IL-15 program is planned to advance into Phase 2b development in vitiligo later this year. Together with the acquisition of BXCL-501 (dexmetomidine sublingual film) from BioXcel Therapeutics, these milestones expand Teva's capabilities in areas of significant unmet need and support its ambition to deliver a sustained cadence of potential launches.

Sustaining our generics powerhouse

Teva continues to strengthen its global generics business through an increased focus on complex generics and biosimilars. While global generics revenues declined primarily due to lower revenues of lenalidomide capsules (a generic version of Revlimid?) in the U.S., revenues from biosimilars continued to expand. Teva currently expects more than $0.8 billion in biosimilars revenues in 2026, reaching its original 2027 revenue objective one year early, with further portfolio expansion supported by new collaborations, including the recently announced agreement with Samsung Bioepis.

Focusing our business

Teva continued to transform and modernize its business through the Teva Transformation programs, which combined with innovative product growth potential, is expected to support the Company's objective of achieving a 30% non-GAAP operating income margin and approximately $700 million of net savings, by 2027 including -two-thirds expected to be realized in 2026. At the same time, Teva continued to maintain disciplined capital allocation and strengthen its financial profile. During Q3 2026, Moody's and S&P upgraded Teva to investment grade, following Fitch's earlier upgrade; and Teva refinanced ~$4.9 billion of debt. All these reflect Teva's goal to achieve two times debt leverage by the end of 2027.

Third Quarter 2026 Consolidated Results

Revenues in the third quarter of 2026 were $4,395 million, a decrease of 2% in both U.S. dollars and local currency terms compared to the third quarter of 2025. This decrease was mainly due to lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid?) in our U.S. segment, partially offset by higher revenues from our key innovative products, primarily AUSTEDO, AJOVY and UZEDY.

Exchange rate movements in the third quarter of 2026, net of hedging effects, positively impacted revenues by $5 million, compared to the third quarter of 2025.

Gross profit in the third quarter of 2026 was $2,440 million, an increase of 6% compared to $2,304 million in the third quarter of 2025. Gross profit margin was 55.5% in the third quarter of 2026, compared to 51.4% in the third quarter of 2025. Non-GAAP gross profit was $2,580 million in the third quarter of 2026, an increase of 4% compared to $2,475 million in the third quarter of 2025. Non-GAAP gross profit margin was 58.7% in the third quarter of 2026, compared to 55.3% in the third quarter of 2025. The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to a favorable mix of products, primarily higher revenues from our key innovative products, largely AUSTEDO, partially offset by lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid).

Research and Development (R&D) expenses, net in the third quarter of 2026, were $297 million, an increase of 16% compared to $256 million in the third quarter of 2025. This increase was mainly due to higher expenses in our immunology and neuroscience projects, as well as in our biosimilars pipeline. Our R&D expenses, net in the third quarters of 2026 and 2025, were also impacted by reimbursements and cost sharing from our strategic partnerships and collaborations entered into in recent years.

Selling and Marketing (S&M) expenses in the third quarter of 2026, were $709 million, an increase of 8% compared to the third quarter of 2025. This increase was mainly due to promotional activities related to our key innovative products, primarily AUSTEDO, and other innovative product launch preparation activities in our U.S. segment.

General and Administrative (G&A) expenses in the third quarter of 2026 were $298 million, a decrease of 6% compared to the third quarter of 2025.

Other Income in the third quarter of 2026 was $68 million, compared to other loss of $7 million in the third quarter of 2025, mainly related to a capital gain from the sale of a property in Europe.

Operating Income was $714 million in the third quarter of 2026, compared to an operating income of $882 million in the third quarter of 2025. Operating Income as a percentage of revenues was 16.2% in the third quarter of 2026, compared to 19.7% in the third quarter of 2025. This decrease was mainly due to higher tangible asset impairments and higher legal settlements and loss contingencies, partially offset by an increase in gross profit. Non-GAAP operating income in the third quarter of 2026 was $1,393 million representing a non-GAAP operating margin of 31.7% compared to $1,294 million representing 28.9%, respectively, in the third quarter of 2025. This increase in non-GAAP operating margin in the third quarter of 2026 was mainly due to higher gross profit margin as described above.

Exchange rate movements in the third quarter of 2026, net of hedging effects, had a negative impact of $2 million on our operating income and non-GAAP operating income compared to the third quarter of 2025.

Financial expenses, net in the third quarter of 2026, were $414 million, mainly comprised of a loss of $224 million on extinguishment of debt and net interest expenses of $174 million. In the third quarter of 2025, financial expenses, net were $237 million, mainly comprised of net interest expenses of $209 million.

In the third quarter of 2026, we recognized a tax expense of $66 million on pre-tax income of $300 million. In the third quarter of 2025, we recognized a tax expense of $214 million on pre-tax income of $646 million.

Our tax rate in the third quarter of 2026 was 22.1%, compared to 33.1% in the third quarter of 2025. Non-GAAP tax rate in the third quarter of 2026 was 16.5%, compared to 14.7% in the third quarter of 2025. Our tax rate and non-GAAP tax rate in the third quarter of 2026 were mainly affected by the generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate and other infrequent or non-recurring items. Our tax rate and non-GAAP tax rate in the third quarter of 2025 were mainly affected by changes in deferred tax balances due to statutory tax rate changes and interest and inflation adjustments related to the agreement with the Israeli Tax Authorities.

Considering the above, we expect our annual non-GAAP tax rate for 2026 to be between 20%-23%, higher than our non-GAAP tax rate for 2025, which was 15.8%.

Net income attributable to Teva and diluted earnings per share in the third quarter of 2026 were $233 million and $0.20, respectively, compared to net income attributable to Teva and diluted earnings per share of $433 million and $0.37, respectively, in the third quarter of 2025. This decrease was mainly due to lower operating income, as discussed above. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share in the third quarter of 2026 were $1,013 million and $0.86, respectively, compared to $910 million and $0.78, respectively, in the third quarter of 2025.

Adjusted EBITDA was $1,496 million in the third quarter of 2026, an increase of 7%, compared to $1,394 million in the third quarter of 2025.

As of September 30, 2026 and 2025, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,195 million shares and 1,184 million shares, respectively.

Non-GAAP information: non-GAAP adjustments in the third quarter of 2026 were $780 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the third quarter of 2026 were adjusted to exclude the following items:

Amortization of purchased intangible assets of $139 million, of which $129 million is included in cost of sales and the remaining $9 million in S&M expenses;

Legal settlements and loss contingencies of $201 million;

Restructuring expenses of $58 million;

Impairment of long-lived assets of $228 million;

Contingent consideration expenses of $2 million;

Equity compensation expenses of $38 million;

Financial expenses of $235 million;

Other non-GAAP items of $14 million; and

Corresponding tax effects and unusual tax items of $134 million.

We believe that excluding such items facilitates investors' understanding of our business including underlying trends, thereby improving the comparability of our business performance results between reporting periods.

For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and for additional information, see the tables below and the information included under "Non-GAAP Financial Measures." Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.

Cash flow generated from operating activities during the third quarter of 2026 was $241 million compared to $369 million in the third quarter of 2025. The lower cash flow generated from operating activities in the third quarter of 2026 resulted mainly from the timing of sales and collections, partially offset by lower legal settlement payments.

During the third quarter of 2026, we generated free cash flow of $495 million, which we define as comprising: $241 million in cash flow generated from operating activities, $327 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $47 million of proceeds from the sale of businesses and long-lived assets, partially offset by $120 million in cash used for capital investments. During the third quarter of 2025, we generated free cash flow of $515 million, which we define as comprising $369 million in cash flow generated from operating activities, $274 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $8 million of proceeds from the sale of businesses and long-lived assets, partially offset by $136 million in cash used for capital investments. The decrease in the third quarter of 2026 resulted mainly from lower cash flow generated from operating activities, as discussed above, partially offset by higher proceeds from the sale of businesses and long-lived assets.

As of September 30, 2026, our debt was $16,718 million, compared to $16,807 million as of December 31, 2025. This decrease was mainly due to $256 million of exchange rate fluctuations. In addition, during the third quarter of 2026, we consummated an early redemption of $4,678 million in aggregate principal amount of senior notes and concurrently, issued $4,837 million of new senior notes, net of discount and issuance costs. The portion of total debt classified as short-term as of September 30, 2026 was 24% compared to 11% as of December 31, 2025. Our financial leverage, which is the ratio between our debt and the sum of our debt and equity, was 68% as of September 30, 2026 and December 31, 2025. Our average debt maturity was approximately 6.3 years as of September 30, 2026, compared to 5.6 years as of December 31, 2025.

Segment Results for the third quarter of 2026

United States Segment

In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under our United States segment. This shift allows the United States segment to continue to manage its entire product portfolio in the region, while strengthening focus on its biopharmaceutical business, growth engines and innovation. As a result, from that date, Anda is reported as part of the Company's Other Activities. Prior period amounts were recast to reflect this change.

The following table presents revenues, expenses and profit for our United States segment for the three months ended September 30, 2026 and 2025:

Three months ended September 30,
	2026			2025
	(U.S. $ in millions / % of Segment Revenues)
Revenues	$	1,870	100 %	$	2,090	100 %
Cost of sales	467		25.0 %	645		30.9 %
Gross profit	1,403		75.0 %	1,446		69.1 %
R&D expenses	196		10.5 %	161		7.7 %
S&M expenses	306		16.4 %	248		11.8 %
G&A expenses	109		5.9 %	113		5.4 %
Other	?		?	(3)		?
Segment profit*	$	791	42.3 %	$	927	44.3 %

_______________________
* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million or 0.5% as applicable.

Revenues from our United States segment in the third quarter of 2026 were $1,870 million, a decrease of 11% compared to the third quarter of 2025, mainly due to lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid?), partially offset by higher revenues from our key innovative products, primarily AUSTEDO, AJOVY, and UZEDY.

Revenues by Major Products and Activities

The following table presents revenues for our United States segment by major products and activities for the three months ended September 30, 2026 and 2025:

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)

Generic products (including biosimilars)	$	718	$	1,175	(39)%
AJOVY	138		73		88%
AUSTEDO	727		601		21%
BENDEKA and TREANDA	30		35		(15)%
COPAXONE	58		62		(8)%
UZEDY	85		43		96%
Other	114		101		13%
Total	$	1,870	$	2,090	(11)%

Generic products (including biosimilar products) revenues in our United States segment in the third quarter of 2026 were $718 million, a decrease of 39% compared to the third quarter of 2025. This decrease was mainly driven by lower revenues from lenalidomide capsules (a generic version of Revlimid) due to increased generic competition in the U.S., partially offset by higher revenues from our portfolio of biosimilar products and from recently launched generic products.

Among the most significant generic products we sold in the United States in the third quarter of 2026 were epinephrine injectable solution (a generic equivalent of EpiPen and EpiPen Jr), TRUXIMA (a biosimilar to Rituxan), and SIMLANDI (a biosimilar to Humira). In the third quarter of 2026, our total prescriptions were approximately 227 million (based on trailing twelve months), representing 5.8% of total U.S. generic prescriptions, compared to approximately 261 million (based on trailing twelve months), representing 6.7% of total U.S. generic prescriptions in the third quarter of 2025, all according to IQVIA data.

On September 28, 2026, we announced that the FDA approved DEGEVMA (denosumab-adet) as a biosimilar to Xgeva (denosumab). DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone, and for the treatment of hypercalcemia of malignancy.

AJOVY revenues in our United States segment in the third quarter of 2026 were $138 million, an increase of 88% compared to the third quarter of 2025, mainly due to a reduction in sales allowance as well as growth in volume. In the third quarter of 2026, AJOVY's exit market share in the United States in terms of total number of prescriptions was 32.8% out of the subcutaneous injectable anti-CGRP class, compared to 32.2% in the third quarter of 2025.

AUSTEDO revenues (which include AUSTEDO XR) in our United States segment in the third quarter of 2026 were $727 million, an increase of 21%, compared to the third quarter of 2025. This increase was mainly due to growth in volume and a favorable business mix including improved net-price realization.

AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023. The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg in July 2024. AUSTEDO XR is a once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington's disease, which is additional to the twice-daily AUSTEDO.

UZEDY (risperidone) extended-release injectable suspension revenues in our United States segment in the third quarter of 2026 were $85 million, an increase of 96% compared to the third quarter of 2025, mainly due to growth in volume.

On October 9, 2026, we announced that the FDA approved WELTRUZA (olanzapine) for extended-release injectable suspension, a new once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. WELTRUZA is expected to become available in the U.S. in the coming weeks, in three different strengths (318 mg, 425 mg, 531 mg). In May 2026, the European Medicines Agency accepted Teva's Marketing Authorization Application for olanzapine LAI (TEV-'749). WELTRUZA is protected in the U.S. by four Orange Book listed patents expiring between 2033 and 2044, and in Europe by five granted patents expiring between 2031 and 2044.

BENDEKA and TREANDA combined revenues in our United States segment in the third quarter of 2026 were $30 million, a decrease of 15% compared to the third quarter of 2025, mainly due to competition from alternative therapies, as well as from branded and generic bendamustine products.

COPAXONE revenues in our United States segment in the third quarter of 2026 were $58 million, a decrease of 8% compared to the third quarter of 2025.

United States Gross Profit

Gross profit from our United States segment in the third quarter of 2026 was $1,403 million, a decrease of 3%, compared to the third quarter of 2025.

Gross profit margin for our United States segment in the third quarter of 2026 increased to 75.0%, compared to 69.1% in the third quarter of 2025. This increase was mainly due to a favorable mix of products, primarily higher revenues from our key innovative products, largely AUSTEDO, partially offset by lower revenues from lenalidomide capsules (a generic version of Revlimid?).

United States Profit

Profit from our United States segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.

Profit from our United States segment in the third quarter of 2026 was $791 million, a decrease of 15% compared to $927 million in the third quarter of 2025. This decrease was mainly due to higher S&M expenses and lower gross profit, as discussed above.

Europe Segment

Our Europe segment includes the European Union, the United Kingdom and certain other European countries.

The following table presents revenues, expenses and profit for our Europe segment for the three months ended September 30, 2026 and 2025:

Three months ended September 30,
	2026			2025
	(U.S. $ in millions / % of Segment Revenues)
Revenues	$	1,319	100 %	$	1,235	100 %
Cost of sales	562		42.6 %	570		46.1 %
Gross profit	757		57.4 %	665		53.9 %
R&D expenses	62		4.7 %	62		5.0 %
S&M expenses	211		16.0 %	225		18.2 %
G&A expenses	64		4.8 %	75		6.1 %
Other	?		?	?		?
Segment profit*	$	420	31.8 %	$	303	24.5 %

_______________________
* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million or 0.5%, as applicable.

Revenues from our Europe segment in the third quarter of 2026 were $1,319 million, an increase of 7% in both U.S. dollars and local currency terms, compared to the third quarter of 2025. This increase was mainly due to higher revenues from generic products, higher proceeds from the sale of certain product rights, and higher revenues from AJOVY.

In the third quarter of 2026, revenues were negatively impacted by exchange rate fluctuations of $7 million, net of hedging effects, compared to the third quarter of 2025. Revenues in the third quarter of 2026 included $17 million from a positive hedging impact, compared to $6 million in the third quarter of 2025, which are included in "Other" in the table below.

Revenues by Major Products and Activities

The following table presents revenues for our Europe segment by major products and activities for the three months ended September 30, 2026 and 2025:

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)

Generic products (including OTC and biosimilars)	$	1,033	$	982	5%
AJOVY	84		66		28%
COPAXONE	38		44		(12)%
Respiratory products	54		52		3%
Other*	111		91		21%
Total	$	1,319	$	1,235	7%

_______________________
* Other revenues in the third quarters of 2026 and 2025 include the sale of certain product rights.

Generic products revenues (including OTC and biosimilar products) in our Europe segment in the third quarter of 2026 were $1,033 million, an increase of 5% compared to the third quarter of 2025. In local currency terms, revenues increased by 7%, mainly due to higher sales of generic and OTC products, including from recently launched products.

AJOVY revenues in our Europe segment in the third quarter of 2026 were $84 million, an increase of 28% compared to the third quarter of 2025. In local currency terms revenues increased by 29% mainly due to higher volumes.

COPAXONE revenues in our Europe segment in the third quarter of 2026 were $38 million, a decrease of 12% compared to the third quarter of 2025. In local currency terms revenues decreased by 11%, mainly due to price reductions and lower volumes resulting from the availability of alternative therapies.

Respiratory products revenues in our Europe segment in the third quarter of 2026 were $54 million, an increase of 3% compared to the third quarter of 2025. In local currency terms, revenues increased by 4%, mainly due to higher volumes as a result of increased supply.

Europe Gross Profit

Gross profit from our Europe segment in the third quarter of 2026 was $757 million, an increase of 14% compared to the third quarter of 2025. Gross profit margin for our Europe segment in the third quarter of 2026 increased to 57.4%, compared to 53.9% in the third quarter of 2025. This increase was mainly due to higher proceeds from the sale of certain product rights and a positive impact from hedging activities.

Europe Profit

Profit from our Europe segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.

Profit from our Europe segment in the third quarter of 2026 was $420 million, an increase of 39%, compared to the third quarter of 2025. This increase was mainly due to higher gross profit, as discussed above.

International Markets Segment

Our International Markets segment includes all countries in which we operate other than the United States and the countries included in our Europe segment. The International Markets segment covers a substantial portion of the global pharmaceutical industry, including more than 35 countries. The countries in our International Markets segment include highly regulated, mainly generic markets, such as Canada and Israel, and branded generics-oriented markets, such as Russia and certain Latin America markets.

As of the date of this Quarterly Report on Form 10-Q, sustained conflict between Russia and Ukraine and disruption in the region is ongoing. Russia and Ukraine markets are included in our International Markets segment results and we have no manufacturing or R&D facilities in these markets. In September 2026, a warehouse that we share with other pharmaceutical companies in Ukraine was damaged, and, as of the date of this Quarterly Report on Form 10-Q, operations at this warehouse resumed. The impact of this conflict on our International Markets segment in the third quarter of 2026 was immaterial.

The following table presents revenues, expenses and profit for our International Markets segment for the three months ended September 30, 2026 and 2025:

	Three months ended September 30,
	2026			2025
	(U.S. $ in millions / % of Segment Revenues)

Revenues	$	592	100 %	$	557	100 %
Cost of sales	276		46.7 %	280		50.2 %
Gross profit	316		53.3 %	278		49.8 %
R&D expenses	31		5.3 %	26		4.6 %
S&M expenses	125		21.2 %	122		21.9 %
G&A expenses	34		5.7 %	36		6.4 %
Other	?		?	?		?
Segment profit*	$	125	21.1 %	$	95	17.0 %

_______________________
* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million or 0.5%, as applicable.

Revenues from our International Markets segment in the third quarter of 2026 were $592 million, an increase of 6% compared to the third quarter of 2025. In local currency terms, revenues increased by 4% compared to the third quarter of 2025, mainly due to higher revenues from our key innovative products AJOVY and AUSTEDO.

In the third quarter of 2026, revenues were positively impacted by exchange rate fluctuations of $13 million, including hedging effects, compared to the third quarter of 2025. Revenues in the third quarter of 2026 included $7 million from a positive hedging impact, compared to $2 million in the third quarter of 2025, which are included in "Other" in the table below.

Revenues by Major Products and Activities

The following table presents revenues for our International Markets segment by major products and activities for the three months ended September 30, 2026 and 2025:

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)

Generic products (including OTC and biosimilars)	$	407	$	421	(3)%
AJOVY	48		30		61%
AUSTEDO	24		17		42%
COPAXONE	8		8		8%
Other*	105		82		28%
Total	$	592	$	557	6%

_______________________
*Other revenues in the third quarters of 2026 and 2025 include the sale of certain product rights.

Generic products revenues (including OTC and biosimilar products) in our International Markets segment in the third quarter of 2026 were $407 million, a decrease of 3% compared to the third quarter of 2025. In local currency terms, revenues decreased by 4%, mainly due to lower revenues from generic and OTC products in certain markets including Ukraine.

AJOVY revenues in our International Markets segment in the third quarter of 2026 were $48 million, an increase of 61% in both U.S. dollars and local currency terms compared to the third quarter of 2025. This increase was mainly due to growth in multiple markets. In April 2026, we announced a strategic partnership for the marketing and distribution of AJOVY in China with Nuerogen (Zhuhai) Pharmaceutical Company Ltd.

AUSTEDO revenues in our International Markets segment in the third quarter of 2026 were $24 million, an increase of 42% compared to the third quarter of 2025. In local currency terms, revenue increased by 34% compared to the third quarter of 2025, mainly due to growth in China.

COPAXONE revenues in our International Markets segment in the third quarter of 2026 were $8 million, an increase of 8% compared to the third quarter of 2025.

International Markets Gross Profit

Gross profit from our International Markets segment in the third quarter of 2026 was $316 million, an increase of 14% compared to the third quarter of 2025.

Gross profit margin for our International Markets segment in the third quarter of 2026 increased to 53.3%, compared to 49.8% in the third quarter of 2025. This increase was mainly due to a favorable mix of products, primarily attributed to higher revenues from AJOVY and AUSTEDO, partially offset by lower revenues from generic products, as discussed above.

International Markets Profit

Profit from our International Markets segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.

Profit from our International Markets segment in the third quarter of 2026 was $125 million, an increase of 32%, compared to the third quarter of 2025. This increase was mainly due to higher gross profit, as discussed above.

Other Activities

We have other sources of revenues, primarily our distribution business in the United States to third parties through Anda, the sale of APIs to third parties, an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis, and certain contract manufacturing services. Our Other Activities are not included in our United States, Europe or International Markets segments described above.

In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under our United States segment. As a result, from that date, Anda is reported as part of our Other Activities. Prior period amounts were recast to reflect this change.

In 2024, we announced that we intend to divest our API business (including its R&D, manufacturing and commercial activities) through a sale. The intention to divest is in alignment with our Pivot to Growth strategy, and Teva is conducting a sales process for this matter. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be completed at all.

Our revenues from Other Activities in the third quarter of 2026 were $613 million, an increase of 3% in both U.S. dollars and local currency terms, compared to the third quarter of 2025.

Anda revenues from third-party products in the third quarter of 2026 were $401 million, an increase of 2%, compared to the third quarter of 2025, mainly due to higher volumes. Anda, our distribution business in the United States, operates independently and distributes generic and innovative medicines and OTC pharmaceutical products from various manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda competes in the distribution market by maintaining a broad portfolio of products, competitive pricing and delivery throughout the United States.

API sales to third parties in the third quarter of 2026 were $115 million, a decrease of 8% in both U.S. dollars and local currency terms, compared to the third quarter of 2025. This decrease was mainly due to lower demand resulting from market dynamics and temporary supply challenges.

Revenues from additional other activities, mainly from Medis and certain contract manufacturing services, were $98 million in the third quarter of 2026, an increase of 21% in U.S. dollars, or 23% in local currency terms compared to the third quarter of 2025, mainly due to higher demand.

2026 Financial Outlook

$ billions, except diluted EPS or as noted	Prior Guidance	Updated Guidance	Key Assumptions
Revenues	$16.5 - $16.85	$16.7 - $17.0	Assume growth in innovative products
AUSTEDO ($m)	2,450 - 2,600	2,550 - 2,650
AJOVY ($m)	850 - 870	930 - 960
UZEDY ($m)	270 - 290	290 - 310
Operating Income*	3.8 - 4.0	3.8 - 3.9	Increase of $0.05B before updating guidance for $0.1B impact of acquired IPR&D charge
Adjusted EBITDA*	4.23 - 4.53	4.23 - 4.43
Finance Expenses*	~$0.8	~$0.8
Tax Rate*	20% - 23%	20% - 23%
Diluted EPS* ($)	1.91 - 2.11	1.92 - 2.11	Increase of $0.08 at midpoint before updating guidance for $0.07 impact of acquired IPR&D charge
Free Cash Flow*	2.0 - 2.4	2.1 - 2.4
CAPEX	0.5	0.5
Foreign Exchange	Volatile swings in FX can negatively impact revenue and income

Financial guidance only assumes business development transactions closed as of November 3, 2026.

*Certain items above are non-GAAP financial measures. For more information, see "Non-GAAP Financial Measures" below. Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.

Conference Call

Teva will host a conference call and live webcast along with a slide presentation on Tuesday, November 3, 2026 at 8:00 a.m. ET to discuss its third quarter 2026 financial results and overall business environment.

A question & answer session will follow.

In order to participate, please register in advance here to obtain a local or toll‐free phone number and your personal pin.

A live webcast of the call will be available on Teva's website at: www.tevapharm.com

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Some amounts in this press release may not add up due to rounding. All percentages have been calculated using unrounded amounts.

Non-GAAP Financial Measures

This press release contains certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures, including, but not limited to, non-GAAP operating income, non-GAAP operating margin, non-GAAP gross profit, non-GAAP gross profit margin, Adjusted EBITDA, free cash flow, non-GAAP tax rate, non-GAAP net income (loss) attributable to Teva and non-GAAP diluted EPS, are presented in order to facilitate investors' understanding of our business. We utilize certain non-GAAP financial measures to evaluate performance in conjunction with other performance metrics. The following are examples of how we utilize the non-GAAP measures: our management and board of directors use the non-GAAP measures to evaluate our operational performance and, to compare our results against work plans and budgets, and ultimately to evaluate the performance of management; our annual budgets are prepared on a non-GAAP basis; and senior management's annual compensation is derived, in part, using these non-GAAP measures. See the attached tables for a reconciliation of the GAAP results to the adjusted non-GAAP measures. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. We are not providing the most comparable forward-looking GAAP measures for non-GAAP metrics included in our financial outlook or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP.

Cautionary Note Regarding Forward-Looking Statements

our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; competition faced by our generic medicines from other pharmaceutical companies; changes in regulatory policy that may result in costs and delays; delays in launches of new generic products; our ability to develop and commercialize additional pharmaceutical products in a timely manner; intense competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline, to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights;
our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all;
our business and operations in general, including: the impact of global geopolitical, economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and our exposure to changes in international trade policies, including the imposition of tariffs in the jurisdictions in which we operate and their effects, and effects related to the agreement we entered into with the U.S. Administration in October 2026, on the pricing and sales of our products, manufacturing and the availability of raw materials; effectiveness of our optimization efforts; significant disruptions of information technology systems, including cybersecurity attacks, as well as risks and uncertainties related to the adoption of artificial intelligence technologies, and breaches of our data security; interruptions in our supply chain or problems with internal or third party manufacturing; challenges associated with conducting business globally, including political or economic instability, prolonged government shutdowns, widespread outbreaks of major diseases and major hostilities or acts of terrorism, such as the ongoing conflict in the Middle East and war involving Iran, and the international responses including economic, trade, financial or other restrictive measures directed specifically at Israel or Israeli companies, and the war between Russia and Ukraine; our ability to attract, hire, integrate and retain highly skilled personnel; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and/or integrate acquisitions successfully and cost-effectively; and our prospects and opportunities for growth if we sell or plan to sell assets or business units and close or divest plants and facilities, as well as our ability to successfully and cost-effectively effectuate and consummate such sales and divestitures, including our planned divestiture of our API business;
compliance, regulatory and litigation matters, including: ongoing legal proceedings, legal settlements and loss contingencies, any failure to comply with complex legal and regulatory requirements, the effects of regulatory uncertainty and changes and the results of increased regulatory oversight, including expenditures required to ensure compliance with research, production and quality control regulations and remedial actions taken to address product issues, such as delayed product launches, product recalls, and facility shutdowns; the effects of governmental, regulatory and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare regulation and related reductions in pharmaceutical pricing, reimbursement and coverage, including as a result of the One Big Beautiful Bill signed into law in the U.S. in July 2025 ("OBBBA"), which will likely reduce the number of insured in Medicaid and Health Insurance Exchange markets, potentially altering utilization patterns and shifting negotiating leverage among payors, our October 2026 agreement with the U.S. Administration referenced above, which followed U.S. Executive Orders issued in April and May 2025 intended to reduce the prices paid for prescription medicines, including Most-Favored-Nation pricing; legal and regulatory actions in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan? (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability to comply with and operate under our deferred prosecution agreement ("DPA") with the U.S. Department of Justice ("DOJ"); potential liability for intellectual property right infringement; significant product liability claims; claims brought by regulatory agencies; failure to comply with complex Medicare, Medicaid and other governmental programs' reporting and payment obligations; compliance with sanctions and trade control laws; environmental risks; and the impact of sustainability issues;
financial, economic and other risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; impairments of our long-lived assets; potential significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; the impact of any failure to maintain effective internal control over our financial reporting; our ability to successfully implement the process for terminating our ADS program and directly listing our ordinary shares in lieu of the ADSs (the "Conversion") and achieve our aims as a result of such Conversion, as further described in Part II, Item 5 our Quarterly Report on Form 10-Q and on our website at ir.tevapharm.com; and;

other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the third quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Consolidated Statements of Income
(U.S. dollars in millions, except share and per share data)
(Unaudited)

			Three months ended				Nine months ended
			September 30,				September 30,
			2026		2025		2026		2025
Net revenues		$	4,395	$	4,480	$	12,519	$	12,547
Cost of sales			1,955		2,176		5,954		6,264
Gross profit			2,440		2,304		6,565		6,282
Research and development expenses			297		256		1,489		746
Selling and marketing expenses			709		656		2,122		1,933
General and administrative expenses			298		317		919		920
Intangible assets impairments			24		64		54		227
Other asset impairments, restructuring and other items			264		62		438		272
Legal settlements and loss contingencies			202		60		504		312
Other loss (income)			(68)		7		(96)		15
Operating income (loss)			714		882		1,135		1,857
Financial expenses, net			414		237		854		714
Income (loss) before income taxes			300		646		282		1,143
Income taxes (benefit)			66		214		254		210
Share in (profits) losses of associated companies, net			*		(2)		*		(4)
Net income (loss)			234		434		27		937
Net income (loss) attributable to redeemable and non-redeemable non-controlling interest			1		1		1		7
Net income (loss) attributable to Teva			233		433		26		930

Earnings (loss) per share attributable to Teva:	Basic	$	0.20	$	0.38	$	0.02	$	0.81
	Diluted	$	0.20	$	0.37	$	0.02	$	0.80
Weighted average number of shares (in millions):	Basic		1,166		1,147		1,162		1,144
	Diluted		1,183		1,164		1,180		1,160

Non-GAAP net income attributable to Teva for diluted earnings per share:**			1,013		910		1,655		2,281
Non-GAAP earnings per share attributable to Teva:**	Diluted	$	0.86	$	0.78	$	1.40	$	1.97

Non-GAAP average number of shares (in millions):	Diluted		1,183		1,164		1,180		1,160


Amounts may not add up due to rounding.

* Represents an amount less than $0.5 million.
** See reconciliation attached.

CONSOLIDATED BALANCE SHEETS
(U.S. dollars in millions, except for share data)
(Unaudited)

	September 30,		December 31,
	2026		2025
ASSETS
Current assets:
Cash and cash equivalents	$	4,085	$	3,556
Accounts receivables, net of allowance for credit losses of $71 million and $81 million as of September 30, 2026 and December 31, 2025, respectively.		3,837		3,709
Inventories		3,173		3,179
Prepaid expenses		1,014		1,122
Other current assets		658		539
Assets held for sale		1,836		1,842
Total current assets		14,602		13,946
Deferred income taxes		2,057		2,191
Other non-current assets		269		405
Property, plant and equipment, net		3,747		4,080
Operating lease right-of-use assets, net		321		345
Identifiable intangible assets, net		3,303		3,781
Goodwill		15,742		16,000
Total assets	$	40,042	$	40,748

LIABILITIES AND EQUITY
Current liabilities:
Short-term debt	$	4,038	$	1,820
Sales reserves and allowances		3,955		4,143
Accounts payables		2,551		2,531
Employee-related obligations		588		739
Accrued expenses		2,962		2,687
Other current liabilities		1,036		1,182
Liabilities held for sale		296		354
Total current liabilities		15,425		13,456

Long-term liabilities:
Deferred income taxes		263		296
Other taxes and long-term liabilities		3,422		3,808
Senior notes and loans		12,680		14,986
Operating lease liabilities		266		288
Total long-term liabilities		16,632		19,379

Equity:
Teva shareholders' equity:		7,979		7,910
Non-controlling interests		5		4
Total equity		7,984		7,914
Total liabilities and equity	$	40,042	$	40,748

Amounts may not add up due to rounding.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. dollars in millions)
(Unaudited)

	Three months ended			Nine months ended
	September 30,			September 30,
		2026	2025		2026	2025
Operating activities:
Net income (loss)	$	234	434	$	27	937
Adjustments to reconcile net income (loss) to net cash provided by operations:
Depreciation and amortization		245	249		725	742
Impairment of long-lived assets and assets held for sale		228	79		350	255
Acquired in-process research and development*		23	17		785	52
Net change in operating assets and liabilities		(682)	(578)		(1,523)	(1,647)
Deferred income taxes ? net and uncertain tax positions		53	107		56	(76)
Stock-based compensation		38	34		121	106
Loss on extinguishment of debt		224	-		224	-
Other items		(53)	27		(65)	122
Net loss (gain) from sale of business and long-lived assets		(69)	-		(89)	-
Net cash provided by (used in) operating activities		241	369		612	491

Investing activities:
Beneficial interest collected in exchange for securitized accounts receivables		327	274		992	932
Purchases of property, plant and equipment and intangible assets		(120)	(136)		(393)	(359)
Proceeds from sale of businesses and long-lived assets, net		47	8		93	34
Purchases of in-process research and development*		(46)	(12)		(747)	(41)
Other investing activities		2	1		3	6
Net cash provided by (used in) investing activities		210	135		(52)	572

Financing activities:
Repayment of senior notes and loans and other long-term liabilities		(4,883)	(444)		(4,906)	(4,112)
Proceeds from senior notes, net of issuance costs		4,845	(7)		4,845	2,298
Purchase of shares from redeemable and non-redeemable non-controlling interests		-	-		-	(38)
Dividends paid to redeemable and non-redeemable non-controlling interests		-	-		-	(340)
Other financing activities		43	(2)		78	1
Net cash provided by (used in) financing activities		6	(453)		18	(2,191)

Effect of exchange rate changes on cash and cash equivalents		(27)	(9)		(49)	31

Net change in cash and cash equivalents		430	42		529	(1,097)
Balance of cash and cash equivalents at beginning of period		3,655	2,161	$	3,556	3,300

Balance of cash and cash equivalents at end of period	$	4,085	2,203	$	4,085	2,203

Non-cash financing and investing activities:
Beneficial interest obtained in exchange for securitized accounts receivables	$	253	296	$	859	937
Receivable for sale of long-lived assets		90	-		90	-

* In the first nine months of 2026, mainly related to the acquisition of Emalex and its primary asset ecopipam (EBS-101).

Amounts may not add up due to rounding.
The accompanying notes are an integral part of the financial statements.

Reconciliation of net income (loss) attributable to Teva
to Non-GAAP net income (loss) attributable to Teva
(Unaudited)
			Three months ended			Nine months ended
			September 30,			September 30,
	($ in millions except per share amounts)		2026	2025		2026	2025
	Net income (Loss) attributable to Teva	$	233	433	$	26	930
	Increase (decrease) for excluded items:
	Amortization of purchased intangible assets		139	144		415	436
	Legal settlements and loss contingencies(1)		201	60		503	309
	Impairment of long-lived assets(2)		228	79		350	255
	Restructuring costs(3)		58	29		121	196
	Equity compensation		38	34		121	106
	Contingent consideration		2	16		25	46
	Financial expenses(4)		235	7		256	58
	Other non-GAAP items(5)		14	51		55	170
	Corresponding tax effects and unusual tax items(6)		(134)	58		(216)	(225)
	Non-GAAP net income attributable to Teva	$	1,013	910	$	1,655	2,281
	Non-GAAP tax rate(7)		16.5 %	14.7 %		22.1 %	16.0 %
	GAAP diluted earnings (loss) per share attributable to Teva	$	0.20	0.37	$	0.02	0.80
	EPS difference(8)		0.66	0.41		1.38	1.16
	Non-GAAP diluted EPS attributable to Teva(8)	$	0.86	0.78	$	1.40	1.97
	Non-GAAP average number of shares (in millions)(8)		1,183	1,164		1,180	1,160

(1)	For the three months ended September 30, 2026, adjustments for legal settlements and loss contingencies mainly consisted of (a) an update to the estimated provision recorded in connection with one of the Company's ongoing antitrust litigations in the amount of $133 million, and (b) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $35 million. For the nine months ended September 30, 2026, adjustments for legal settlements and loss contingencies mainly consisted of (a) an estimated provision recorded in connection with one of the Company's ongoing antitrust litigations in the amount of $250 million, and (b) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $132 million. For the three and nine months ended September 30, 2025, adjustments of legal settlements and loss contingencies mainly consisted of (a) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $42 million and $139 million, respectively, and (b) an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the U.S. in the generic drug antitrust litigation in the amount of $55 million.
(2)	The expense for the three and nine months ended September 30, 2026, mainly consisted of (a) impairment charges in connection with several manufacturing facilities in Europe in the amount of $140 million and $210 million, respectively, and (b) impairment charges in connection with the held for sale measurement of the API business (including its R&D, manufacturing and commercial activities), which includes an impact related to the expected gain from reclassification of currency translation adjustments in the amount of $49 million and $66 million, respectively. For the nine months ended September 30, 2025, the adjustment for impairment of long-lived assets was mainly related to intangible assets in the U.S. and Europe.
(3)	In the nine months ended September 30, 2026 and 2025, Teva recorded restructuring expenses of $121 million and $196 million, respectively, primarily related to optimization activities in connection with Teva's Transformation programs related to Teva's global organization and operations mainly through headcount reduction.
(4)	In the three and nine months ended September 30, 2026, Teva recorded $224 million of finance expenses related to a loss on extinguishment of debt.
(5)	Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to material litigation fees, rationalization of our plants, accelerated depreciation and other unusual events.
(6)	Adjustments for corresponding tax effects and unusual tax items exclusively consisted of the tax impact directly attributable to the pre-tax items that are excluded from non-GAAP net income included in the other adjustments to this table.
(7)	Non-GAAP tax rate is tax expenses (benefit) excluding the impact of non-GAAP tax adjustments presented above as a percentage of income (loss) before income taxes excluding the impact of non-GAAP adjustments presented above. Our non-GAAP tax rate in the nine months ended September 30, 2026 was mainly affected by an unfavorable tax impact of a non-deductible acquired IPR&D charge related to the acquisition of Emalex and its primary asset ecopipam (EBS-101), the generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, and other infrequent or non-recurring items, such as internal legal entities reorganization.
(8)	EPS difference and diluted non-GAAP EPS are calculated by dividing our non-GAAP net income attributable to Teva by our non-GAAP diluted weighted average number of shares.

Reconciliation of gross profit to Non-GAAP gross profit
(Unaudited)
		Three months ended			Nine months ended
		September 30,			September 30,
($ in millions)		2026	2025		2026	2025
Gross profit	$	2,440	2,304	$	6,565	6,282
Gross profit margin		55.5%	51.4%		52.4%	50.1%
Increase (decrease) for excluded items: (1)
Amortization of purchased intangible assets		129	134		387	406
Equity compensation		6	6		18	17
Other non-GAAP items		5	32		11	101
Non-GAAP gross profit	$	2,580	2,475	$	6,981	6,807
Non-GAAP gross profit margin (2)		58.7%	55.3%		55.8%	54.3%

(1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table.
(2) Non-GAAP gross profit margin is non-GAAP gross profit as a percentage of revenue.

Reconciliation of operating income (loss) to Non-GAAP operating income (loss)
(Unaudited)

		Three months ended			Nine months ended
		September 30,			September 30,
($ in millions)		2026	2025		2026	2025
Operating income (loss)	$	714	882	$	1,135	1,857
Operating margin		16.2 %	19.7 %		9.1 %	14.8 %
Increase (decrease) for excluded items: (1)
Amortization of purchased intangible assets		139	144		415	436
Legal settlements and loss contingencies		201	60		503	309
Impairment of long-lived assets		228	79		350	255
Restructuring costs		58	29		121	196
Equity compensation		38	34		121	106
Contingent consideration		2	16		25	46
Loss (gain) on sale of business		(1)	6		(5)	19
Other non-GAAP items		15	45		60	149
Non-GAAP operating income (loss)	$	1,393	1,294	$	2,724	3,373
Non-GAAP operating margin(2)		31.7 %	28.9 %		21.8 %	26.9 %

(1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table.
(2) Non-GAAP operating margin is Non-GAAP operating income as a percentage of revenues.

Reconciliation of net income (loss) to adjusted EBITDA
(Unaudited)
			Three months ended			Nine months ended
			September 30,			September 30,
($ in millions)			2026	2025		2026	2025
Net income (loss)		$	234	434	$	27	937
Increase (decrease) for excluded items:(1)
	Financial expenses		414	237		854	714
	Income taxes		66	214		254	210
	Share in profits (losses) of associated companies ?net		?	(2)		?	(4)
	Depreciation		106	105		311	306
	Amortization		139	144		415	436
EBITDA			959	1,131		1,861	2,599
	Legal settlements and loss contingencies		201	60		503	309
	Impairment of long lived assets		228	79		350	255
	Restructuring costs		58	29		121	196
	Equity compensation		38	34		121	106
	Contingent consideration		2	16		25	46
	Loss (Gain) on sale of Business		(1)	6		(5)	19
	Other non-GAAP items		12	40		50	137
Adjusted EBITDA		$	1,496	1,394	$	3,025	3,668

(1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table.
? Represents an amount of less than $0.5 million.

Segment Information
(Unaudited)

	United States					Europe						International Markets
	Three months ended September 30,					Three months ended September 30,						Three months ended September 30,
	2026		2025			2026			2025			2026			2025

	(U.S. $ in millions)					(U.S. $ in millions)						(U.S. $ in millions)

Revenues	$	1,870		$	2,090		$	1,319		$	1,235		$	592		$	557
Cost of sales	467			645			562			570			276			280
Gross profit	1,403			1,446			757			665			316			278
R&D expenses	196			161			62			62			31			26
S&M expenses	306			248			211			225			125			122
G&A expenses	109			113			64			75			34			36
Other	?			(3)			?			?			?			?
Segment profit*	$	791		$	927		$	420		$	303		$	125		$	95

* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million.

Segment Information
Unaudited

	United States				Europe				International Markets
	Nine months ended September 30,				Nine months ended September 30,				Nine months ended September 30,
	2026		2025		2026		2025		2026		2025

	(U.S. $ in millions)				(U.S. $ in millions)				(U.S. $ in millions)

Revenues	$	5,106	$	5,413	$	3,922	$	3,726	$	1,666	$	1,634
Cost of sales		1,462		1,742		1,727		1,687		823		835
Gross profit		3,644		3,670		2,195		2,039		843		799
R&D expenses		1,226		467		159		181		80		75
S&M expenses		898		741		648		652		370		353
G&A expenses		307		319		203		210		111		107
Other income		(9)		(1)		(3)		?		(8)		(3)
Segment profit	$	1,222	$	2,143	$	1,188	$	996	$	289	$	266

* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million.

Reconciliation of our segment profit
to consolidated income (loss) before income taxes
	Three months ended
	September 30,
		2026		2025
	(U.S.$ in millions)

United States profit	$	791	$	927
Europe profit		420		303
International Markets profit		125		95
Total reportable segment profit		1,336		1,325
Profit (loss) of other activities		57		(31)
Amounts not allocated to segments:
Amortization		139		144
Other asset impairments, restructuring and other items		264		62
Intangible asset impairments		24		64
Legal settlements and loss contingencies		201		60
Other unallocated amounts		51		82
Consolidated operating income (loss)		714		882
Financial expenses - net		414		237
Consolidated income (loss) before income taxes	$	300	$	646

Reconciliation of our segment profit
to consolidated income (loss) before income taxes
	Nine months ended September 30,
	September 30,
	2026		2025
	(U.S.$ in millions)

United States profit	$	1,222	$	2,143
Europe profit		1,188		996
International Markets profit		289		266
Total reportable segment profit		2,699		3,405
Profit (loss) of other activities		25		(32)
Amounts not allocated to segments:
Amortization		415		436
Other asset impairments, restructuring and other items		438		272
Intangible asset impairments		54		227
Legal settlements and loss contingencies		503		309
Other unallocated amounts		179		272
Consolidated operating income (loss)		1,135		1,857
Financial expenses - net		854		714
Consolidated income (loss) before income taxes	$	282	$	1,143

Segment revenues by major products and activities
(Unaudited)

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)
United States segment
Generic products (including biosimilars)	$	718	$	1,175	(39)%
AJOVY		138		73	88 %
AUSTEDO		727		601	21 %
BENDEKA and TREANDA		30		35	(15)%
COPAXONE		58		62	(8)%
UZEDY		85		43	96 %
Other		114		101	13 %
Total		1,870		2,090	(11)%


	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)
Europe segment
Generic products (including OTC and biosimilars)	$	1,033	$	982	5 %
AJOVY		84		66	28 %
COPAXONE		38		44	(12)%
Respiratory products		54		52	3 %
Other*		111		91	21 %
Total		1,319		1,235	7 %

*Other revenues in the third quarter of 2026 and 2025 include the sale of certain product rights

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)
International Markets segment
Generic products (including OTC and biosimilars)	$	407	$	421	(3)%
AJOVY		48		30	61 %
AUSTEDO		24		17	42 %
COPAXONE		8		8	8 %
Other*		105		82	28 %
Total		592		557	6 %

*Other revenues in the third quarter of 2026 and 2025 include the sale of certain product rights

Segment revenues by major products and activities
(Unaudited)

	Nine months ended
	September 30,				Percentage Change
	2026		2025		2025-2026
	(U.S.$ in millions)
United States segment
Generic products	$	1,990	$	2,984	(33)%
AJOVY		341		190	80 %
AUSTEDO		1,963		1,492	32 %
BENDEKA / TREANDA		85		111	(24)%
COPAXONE		182		179	2 %
UZEDY		225		136	65 %
Other		321		321	?
Total		5,106		5,413	(6)%

? Represents an amount less than 0.5%.

	Nine months ended
	September 30,				Percentage Change
	2026		2025		2025-2026
	(U.S.$ in millions)
Europe segment
Generic products	$	3,146	$	3,011	4 %
AJOVY		238		195	22 %
COPAXONE		127		135	(6)%
Respiratory products		171		162	6 %
Other*		241		223	8 %
Total		3,922		3,726	5 %

*Other revenues in the first nine months of 2026 and 2025 include the sale of certain product rights.

	Nine months ended
	September 30,				Percentage Change
	2026		2025		2025-2026
	(U.S.$ in millions)
International Markets segment
Generic products	$	1,212	$	1,298	(7)%
AJOVY		130		78	68 %
AUSTEDO		63		34	82 %
COPAXONE		22		25	(13)%
Other*		239		199	20 %
Total		1,666		1,634	2 %

*Other revenues in the first nine months of 2026 and 2025 include the sale of certain product rights.

Free cash flow reconciliation
(Unaudited)

		Three months ended September 30,
		2026		2025
	(U.S. $ in millions)

Net cash provided by (used in) operating activities		241		369
Beneficial interest collected in exchange for securitized account receivables		327		274
Capital investment		(120)		(136)
Proceeds from sale of businesses and long-lived assets, net		47		8
Free cash flow	$	495	$	515

Free cash flow reconciliation
(Unaudited)

	Nine months ended September 30,
	2026		2025

	(U.S. $ in millions)

Net cash provided by (used in) operating activities		612		491
Beneficial interest collected in exchange for securitized trade receivables		992		932
Capital investment		(393)		(359)
Proceeds from sale of businesses and long-lived assets, net		93		34
Free cash flow	$	1,305	$	1,098

Net debt reconciliation
unaudited

		September 30,
	2026
Short-term debt		4,038
Senior notes and loans		12,680
Total debt		16,718
Net of cash and cash equivalents		4,085
Net debt	$	12,633

Seyond Expands Smart City Solution with LiDAR-Powered Operational Twin Capabilities and Technology Collaborations

Tue, 03 Nov 2026 22:22:00 +0700

Combining comprehensive LiDAR sensing, agentic AI-powered analytics, and technology collaborations to advance smart cities, critical infrastructure and safe spaces.

SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Seyond, a global provider of high-performance LiDAR solutions, is expanding its smart city and smart spaces solutions through advanced 3D sensing and technology collaborations.

By connecting spatial data with agentic AI-powered analytics and computing platforms, Seyond helps organizations improve safety, transportation, and infrastructure operations.

Growing Demand for Smart Cities and Intelligent Infrastructure

Smart cities are becoming an operational priority as organizations seek real-time intelligence to improve safety, transportation and operational efficiency. According to LP Information, the global smart-city LiDAR market was valued at approximately $358 million in 2025, with a projected compound annual growth rate of 18.7%, suggesting a market of approximately $425 million in 2026.

Demand for spatial intelligence now extends beyond roadways to airports, stadiums, utilities, data centers, and other critical infrastructures. These applications create opportunities to better understand movement, optimize space utilization, and improve operations.

Based on industry research and internal assumptions, Seyond estimates an illustrative annual serviceable addressable market of $1.3 billion to $2.0 billion in 2026 for expanded stationary LiDAR applications outside China. This sensor-focused estimate represents potential market opportunity, not projected company revenue.

Seyond: Enabling Spatial Intelligence Across Smart Environments

Seyond's comprehensive LiDAR portfolio, spanning ultra-long-range to short-range sensing, supports applications from transportation infrastructure to localized indoor and outdoor environments. Its technology generates high-resolution 3D spatial data to measure vehicle movement, pedestrian flows, and environmental activity without relying on identifiable photographic imagery, providing a privacy-conscious foundation for spatial analytics.

These capabilities support continuous spatial awareness across intersections, transportation hubs, commercial facilities, and public gathering spaces. Combined with AI-powered analytics and computing platforms, Seyond's sensing technology helps organizations translate physical-world data into actionable insights, enabling more responsive infrastructure and better-informed operational decisions.

Expanding Technology Collaborations to Deliver Complete Operational Twin Solutions

Delivering practical smart city solutions increasingly requires collaboration across sensing, computing, AI, and software. One example is the digital operational twins, dynamic digital representation of a physical environment that reflects activity and movement in real time, helping operators understand changing conditions and make informed decisions.

At Smart City Expo World Congress 2026, November 3-5 in Barcelona, Seyond will participate as an exhibition partner at the Dell Technologies booth, showcasing a live LiDAR-powered operational twin.

By combining Seyond's sensing capabilities with technologies from Dell and NVIDIA, the demonstration will illustrate how integrated solutions can support pedestrian-flow analysis, space utilization, and real-time operational awareness. The solution will feature a Dell Technologies system powered by the NVIDIA DGX Spark, which combines a 20-core Arm Grace CPU with an NVIDIA Blackwell GPU.

Fused data from LiDAR, video, and other sensors feeds a live operational twin, giving operators a unified view of activity across the environment. The solution integrates vision AI agents built with NVIDIA Metropolis Blueprint for video search and summarization (VSS) and NVIDIA Cosmos to enhance scene understanding and support informed operational decisions.

Seyond is also collaborating with AMSYS to advance integrated spatial intelligence solutions for large-scale venues and public environments. Combining Seyond's LiDAR sensing with the AMSYS Fusion Core Perception Platform, these solutions are designed to translate anonymous movement and occupancy data into actionable operational insights.

In a stadium or major event venue, for example, this approach could help operators monitor crowd density, analyze queues, and identify congestion across entrances and gathering areas. These insights could support better decisions about staffing, crowd movement, and resource allocation while maintaining a privacy-conscious approach to sensing.

Together, these collaborations demonstrate Seyond's expanding role in connecting advanced sensing with AI, computing, and operational software. As investment in intelligent infrastructure grows, Seyond remains focused on bringing practical spatial intelligence solutions to cities, critical infrastructure and safe spaces.

About Seyond

Seyond is a global provider of high-performance LiDAR solutions for automotive, robotics, intelligent transportation, smart infrastructure, and other applications. Its comprehensive portfolio of advanced 3D sensing technologies enables accurate, reliable spatial intelligence across a wide range of environments.

Hopscotch launches Hopscotch Public Engagement, a new entity dedicated to the European institutions

Tue, 03 Nov 2026 22:19:00 +0700

Press release

Paris, November 3rd 2026 --

Hopscotch launches Hopscotch Public Engagement, a new entity dedicated to the European institutions

The communications Group is combining its integrated expertise and international network to support the EU institutions meet their communication challenges and the demands of major public contracts.

HOPSCOTCH, the international communications Group founded in France, today announces the launch of Hopscotch Public Engagement. The new Brussels-based entity will primarily serve the EU institutions and, more broadly, the European public sector.

The launch reflects the Group's ambition to strengthen its presence with the EU institutions. Much of their communication work is commissioned through multi-year framework contracts spanning several areas of expertise and several countries. Hopscotch Public Engagement will meet these needs by drawing on the strengths of an integrated communications group: specialist expertise, sector knowledge and the ability to deliver across Europe.

An integrated offer built for the challenges of public communication

From 360? communication campaigns to events, digital, influence and public relations, Hopscotch Public Engagement brings together the Group's expertise to design and deliver communication strategies suited to the complexity of EU issues. This integrated approach meets the wide range of the institutions'needs. It is also built for framework contracts, which are typically split into multiple lots and require several disciplines and teams to work in close coordination.

The entity builds on the experience HOPSCOTCH has developed with private- and public-sector clients, adapting it to the conventions and requirements of EU institutional communication. This includes the Group's approaches to Relational Capital and augmented public relations, which help institutions explain their work, strengthen dialogue with their audiences and deliver their messages at the right time.

The offer relies on the Group's sector expertise and international network. As an independent European group, HOPSCOTCH has more than 40 offices worldwide. Its organisation is designed to support pan-European campaigns and to coordinate communication programmes across European markets.

The Group also draws on the experience of its international network, formerly Sopexa, in supporting regulated sectors and European programmes for agriculture and food industry players. It also runs international campaigns on behalf of the European Commission's Directorate-General for Agriculture and Rural Development (DG AGRI) and the European Research Executive Agency (REA).

"The launch of Hopscotch Public Engagement reflects a conviction the Group holds firmly: the biggest communication challenges now play out at European level. With this new entity, we are combining in-depth knowledge of the institutions with our network's ability to coordinate programmes across European and international markets," says Sylvain Rouchy, Vice President, Global Operations at HOPSCOTCH.

Based in Brussels, Hopscotch Public Engagement works alongside Hopscotch Belgium, the Group's brand communication agency for the Belgian market, led by M?lanie Rouchy.

"Setting up Hopscotch Public Engagement in Brussels is a great opportunity to strengthen synergies within the Group and to put our complementary expertise at the service of the European institutions," says M?lanie Rouchy, Managing Director of Hopscotch Belgium.

A shared ambition to serve Europe

Hopscotch Public Engagement is co-led by Caroline Danloy and Nicolas Balland. Between them, they bring knowledge of the European institutions, communications expertise and experience in leading multidisciplinary teams.

Caroline Danloy has extensive experience in strategic communication for international and European institutional clients. Over a 25-year career, she has served as Vice President at ICF Next, where she led 360? communication teams delivering major European campaigns.

"We are at a turning point for European democracy. Communicating about the work of the European institutions and the challenges they face is more important than ever, and it is a mission I have been proud to carry out for 25 years," says Caroline Danloy, Co-Managing Director of Hopscotch Public Engagement.

"Hopscotch brings a rare combination to this market: the scale and maturity of an international network headquartered in France, expertise spanning the public and private sectors, and real depth of subject knowledge. Communicating for public institutions involves many topics and stakeholders, and this combination is exactly what that complexity demands. Alongside Nicolas, whose experience I know well, I look forward to putting these strengths at the service of the European institutions with Hopscotch Public Engagement."

Nicolas Balland brings more than 20 years of experience in the communications industry, particularly in events, public relations and institutional communication. After holding various roles at ICF Next, he joined Tipik, where he led Event, Studio and Audiovisual teams before becoming Managing Director.

"This is a project Caroline and I had been thinking about for several years. When we met Hopscotch, we quickly realised that we shared the same ambition," explains Nicolas Balland, Co-Managing Director of Hopscotch Public Engagement.

"Today, we are proud to offer the European institutions the strength of a leading communications Group, combined with distinctive expertise and in-depth knowledge of European issues. Our ambition goes beyond designing and delivering communication campaigns: we want to build an organisation that connects institutions, citizens and ideas, and that takes concrete action for Europe."

About HOPSCOTCH

HOPSCOTCH is an international communications Group founded in France, driven by an entrepreneurial vision and the complementary nature of its talents and expertise.

HOPSCOTCH is a unique combination of expertise, driven by the belief that the value of a company or organisation lies in the quality of its Relational Capital.

With more than 1,200 employees, half of whom are based internationally (40 offices across 5 continents), HOPSCOTCH covers all areas of communication: influence, events, public relations, activations, digital, internal communication, public affairs, and marketing services.

HOPSCOTCH organises its agencies around its areas of expertise:

Event: Hopscotch Event, Hopscotch Congr?s, Hopscotch Moments, Sagarmatha.

Public Relations: Hopscotch PR, Le Public Syst?me PR, Human to Human, Hopscotch D?cideurs.

Digital and Marketing: heaven, AD Crew, Hopscotch Digital Studio, Sublime.

Media: Hopscotch Media

Sectorial expertise: Hopscotch Cin?ma, Hopscotch Luxe, Hopscotch Season, Hopscotch Sport, Hopscotch Tourism.

HOPSCOTCH has been committed to ambitious ecological and societal initiatives for over 15 years, validated by internationally recognized CSR certifications, including RSE Agences Actives, ISO 20121, and the EcoVadis Gold medal.

In 2026, HOPSCOTCH was named "Global Agency of the Year" by PRovoke Media.

Listed on Euronext Growth Paris (Ticker code: ALHOP FR ; ISIN code: FR 00000 6527 8), the Group represents a turnover of ?270,8 million and a gross margin of ?98,8 million in 2025.

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Tue, 03 Nov 2026 21:54:00 +0700

*Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO upon close and infliximab-abda in Q3 2027

*Collaboration combines Samsung Bioepis' biosimilar expertise with Teva's commercial capabilities

*Agreement expands collaboration with Samsung Bioepis, strengthening Teva's generics powerhouse and biosimilars portfolio as part of its Pivot to Growth strategy

TEL AVIV, Israel and INCHEON, South Korea, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Samsung Bioepis Co., Ltd. today announced that they have entered into a license and commercialization agreement for two FDA-approved immunology biosimilars: infliximab-abda, a biosimilar to Remicade 1 (infliximab) and ETICOVO (etanercept-ykro), a biosimilar to Enbrel 2 (etanercept).

Under the terms of the agreement, Teva will obtain U.S. commercialization rights to etanercept-ykro at closing, while U.S. commercialization rights to infliximab-abda will transfer to Teva in Q3 2027. The timing of Teva's future U.S. commercialization of etanercept-ykro will be announced at a later date. Samsung Bioepis will remain responsible for regulatory oversight and manufacturing of both products. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals, and is currently anticipated to close by the end of 2026.

"This agreement strengthens our collaboration with Samsung Bioepis and will expand our U.S. immunology portfolio with two additional biologic treatment options," said Richard Francis, President and CEO of Teva. "Biosimilars are an important part of our Pivot to Growth strategy, helping us build a stronger portfolio while expanding access to high-quality medicines. Together, we have an opportunity to bring more treatment choices to patients living with chronic inflammatory conditions."

"We are delighted to expand our strategic alliance with Teva to strengthen the commercial footprint of our immunology portfolio in the U.S.," said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. "Infliximab-abda has established a proven track record of clinical efficacy and supply reliability since its launch, while ETICOVO represents an FDA-approved therapy poised to broaden treatment choices for patients. By pairing our dedication to high-quality biologic development and manufacturing with Teva's commercial reach across U.S. healthcare channels, we aim to ensure uninterrupted treatment continuity for existing patients and bring sustainable value to the U.S. healthcare system."

Under the terms of the agreement and subject to certain conditions, Teva will pay Samsung Bioepis an upfront payment over the next 3 years. Samsung Bioepis may be eligible for additional launch and sales milestones payments. Teva and Samsung Bioepis will share profit from the commercialization of these products.

The agreement builds on a series of biosimilar collaborations between Teva and Samsung Bioepis. In 2025, the companies announced a U.S. agreement for EPYSQLI (eculizumab-aagh), a biosimilar to Soliris3 (eculizumab). In 2026, the companies announced two agreements, including one for OPUVIZ (aflibercept) in Canada and a separate global agreement to license, develop and commercialize up to six potential biosimilar candidates currently in early-stage development, including biosimilar candidates referencing Fasenra4 (benralizumab) and Ilaris5 (canakinumab).

About Infliximab-abda and etanercept-ykro

Both biosimilars are tumor necrosis factor (TNF) inhibitors indicated for the treatment of chronic inflammatory and autoimmune conditions:

infliximab-abda6 was approved by the FDA in 2017 for indications including Crohn's disease (adult and pediatric), ulcerative colitis (adult and pediatric), rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Teva will newly assume commercialization of the product, scheduled to take effect in the third quarter of 2027.

etanercept-ykro7 was approved by the FDA in 2019 and is not currently available on the U.S. market. It is approved for indications including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (patients aged 2 years and older), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis (patients aged 4 years and older).

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR INFLIXIMAB-ABDA

SERIOUS INFECTIONS

Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue infliximab-abda if a patient develops a serious infection or sepsis.

Reported infections include:

Active tuberculosis (TB), including reactivation of latent TB. Patients frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before infliximab-abda use and during therapy. Treatment for latent infection should be initiated prior to infliximab-abda use.

Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, pneumocystosis, and cryptococcosis. Patients may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.

Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella, Listeria, and Salmonella.

The risks and benefits of treatment with infliximab-abda should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with infliximab-abda, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy, who are on treatment for latent TB, or who were previously treated for TB infection.

Risk of infection may be higher in patients greater than 65 years of age, pediatric patients, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressant therapy. In clinical trials, other serious infections observed in patients treated with infliximab products included pneumonia, cellulitis, abscess, and skin ulceration.

MALIGNANCIES

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. Approximately half of these cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months after the first dose of therapy. Most of the patients were receiving concomitant immunosuppressants.

Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported cases have occurred in patients with Crohn's disease or ulcerative colitis and most were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treatment with infliximab-abda, especially in these patient types.

In clinical trials of all TNF inhibitors, more cases of lymphoma were observed compared with controls and the expected rate in the general population. However, patients with Crohn's disease, rheumatoid arthritis, or plaque psoriasis may be at higher risk for developing lymphoma. In clinical trials of some TNF inhibitors, including infliximab products, more cases of other malignancies were observed compared with controls. The rate of these malignancies among patients treated with infliximab products was similar to that expected in the general population whereas the rate in control patients was lower than expected. Cases of acute and chronic leukemia have been reported with postmarketing TNF-blocker use. As the potential role of TNF inhibitors in the development of malignancies is not known, caution should be exercised when considering treatment of patients with a current or a past history of malignancy or other risk factors such as chronic obstructive pulmonary disease (COPD).

Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-blocker therapy, including infliximab products. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.

A population-based retrospective cohort study found a 2- to 3-fold increase in the incidence of invasive cervical cancer in women with rheumatoid arthritis treated with infliximab compared to biologics-na?ve patients or the general population, particularly those over 60 years of age. A causal relationship between infliximab products and cervical cancer cannot be excluded. Periodic screening should continue in women treated with infliximab products.

CONTRAINDICATIONS

The use of infliximab-abda at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure. infliximab-abda is contraindicated in patients with a previous severe hypersensitivity reaction to infliximab products or any of the inactive ingredients of infliximab-abda or any murine proteins (severe hypersensitivity reactions have included anaphylaxis, hypotension, and serum sickness).

WARNINGS AND PRECAUTIONS

HEPATITIS B REACTIVATION

TNF inhibitors, including infliximab products, have been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases were fatal. Patients should be tested for HBV infection before initiating INFLIXIMAB-ABDA. For patients who test positive, consult a physician with expertise in the treatment of hepatitis B. Exercise caution when prescribing infliximab-abda for patients identified as carriers of HBV and monitor closely for active HBV infection during and following termination of therapy with INFLIXIMAB-ABDA. Discontinue infliximab-abda in patients who develop HBV reactivation and initiate antiviral therapy with appropriate supportive treatment. Exercise caution when considering resumption of infliximab-abda and monitor patients closely.

HEPATOTOXICITY

Severe hepatic reactions, including acute liver failure, jaundice, hepatitis, and cholestasis have been reported rarely in patients receiving infliximab products postmarketing. Some cases were fatal or required liver transplant. Aminotransferase elevations were not noted prior to discovery of liver injury in many cases. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations (eg, ≥5 times the upper limit of normal) develop, infliximab-abda should be discontinued, and a thorough investigation of the abnormality should be undertaken.

HEMATOLOGIC EVENTS

Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported in patients using infliximab products. The causal relationship to infliximab therapy remains unclear. Exercise caution in patients who have ongoing or a history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs and symptoms of blood dyscrasias or infection. Consider discontinuation of infliximab-abda in patients who develop significant hematologic abnormalities.

HYPERSENSITIVITY

Infliximab products have been associated with hypersensitivity reactions that differ in their time of onset and required hospitalization in some cases. Most hypersensitivity reactions (including anaphylaxis, urticaria, dyspnea, and/or hypotension) have occurred during or within 2 hours of infliximab product infusion. Serious infusion reactions including anaphylaxis were infrequent. infliximab-abda should be discontinued for severe hypersensitivity reactions. Medications for the treatment of hypersensitivity reactions should be available.

CARDIOVASCULAR AND CEREBROVASCULAR REACTIONS DURING AND AFTER INFUSION

Serious cerebrovascular accidents, myocardial ischemia/infarction (some fatal), hypotension, hypertension, and arrhythmias have been reported during and within 24 hours of initiation of infliximab infusion. Cases of transient visual loss have been reported during or within 2 hours of infusion of infliximab. Monitor patients during infusion and, if a serious reaction occurs, discontinue infusion. Manage reactions according to signs and symptoms.

NEUROLOGIC EVENTS

TNF inhibitors, including infliximab products, have been associated in rare cases with central nervous system (CNS) manifestation of systemic vasculitis, seizure, and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barr? syndrome. Exercise caution when considering infliximab-abda in patients with these disorders and consider discontinuation if these disorders develop.

AUTOIMMUNITY

Treatment with infliximab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

DRUG INTERACTIONS

USE WITH OTHER DRUGS

Concurrent use of infliximab-abda with other biological products used to treat the same conditions as infliximab-abda is not recommended because of the possibility of an increased risk of infection. Care should be taken when switching from one biologic to another, since overlapping biological activity may further increase the risk of infection.

VACCINATIONS AND USE OF LIVE VACCINES/THERAPEUTIC INFECTIOUS AGENTS

Prior to initiating infliximab-abda in pediatric and adult patients, update vaccinations in accordance with current vaccination guidelines. Live vaccines or therapeutic infectious agents should not be given with infliximab-abda due to the possibility of clinical infections, including disseminated infections.

At least a 6-month waiting period following birth is recommended before the administration of any live vaccine to infants exposed in utero to infliximab products.

ADVERSE REACTIONS

In clinical trials, the most common adverse reactions occurring in >10% of patients included infections (e.g., upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain.

INDICATIONS

Infliximab-abda is a TNF blocker indicated for:

Crohn's Disease

Infliximab-abda is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy.

Infliximab-abda is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn's disease.

Pediatric Crohn's Disease

Infliximab-abda is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age or older with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy.

Ulcerative Colitis

Infliximab-abda is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

Pediatric Ulcerative Colitis

Infliximab-abda is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

Rheumatoid Arthritis

Infliximab-abda is indicated, in combination with methotrexate (MTX), for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA).

Ankylosing Spondylitis

Infliximab-abda is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS).

Psoriatic Arthritis

Infliximab-abda is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA).

Plaque Psoriasis

Infliximab-abda is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. Infliximab-abda should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Please read the Full Prescribing Information, including BOXED WARNINGS and Medication Guide.

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR ETICOVO (etanercept-ykro)

SERIOUS INFECTIONS

Patients treated with etanercept products are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ETICOVO should not be initiated in the presence of sepsis, active infections, or allergy to ETICOVO or its components. ETICOVO should be discontinued if a patient develops a serious infection or sepsis.

Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before ETICOVO use and periodically during therapy. Initiate treatment for latent infection prior to ETICOVO use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with ETICOVO should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with ETICOVO, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.

MALIGNANCIES

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including etanercept products.

In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA patients. The role of TNF blocker therapy in the development of malignancies is unknown.

Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population.

Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including etanercept products. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.

Pediatric Patients

In patients who initiated therapy at ≤18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin's and non-Hodgkin's lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.

CONTRAINDICATIONS

ETICOVO is contraindicated in patients with sepsis.

WARNINGS AND PRECAUTIONS

NEUROLOGIC REACTIONS

Treatment with TNF-blocking agents, including etanercept products, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barr? syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ETICOVO therapy. Prescribers should exercise caution in considering the use of ETICOVO in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders.

NEW ONSET OR WORSENING OF HEART FAILURE

Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking etanercept products. Caution should be used when using ETICOVO in patients with CHF. These patients should be carefully monitored.

HEMATOLOGIC REACTIONS

Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to etanercept products therapy remains unclear. Exercise caution when considering ETICOVO in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ETICOVO if significant hematologic abnormalities are confirmed.

HEPATITIS B REACTIVATION

Reactivation of hepatitis B has been reported in patients who were previously infected with hepatitis B virus (HBV) and received concomitant TNF-blocking agents, including etanercept products. Most reports occurred in patients also taking immunosuppressive agents, which may contribute to hepatitis B reactivation. Exercise caution when considering ETICOVO in these patients.

ALLERGIC REACTIONS

Allergic reactions associated with administration of ETICOVO during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, discontinue administration of ETICOVO and initiate appropriate therapy immediately.

IMMUNIZATIONS

Avoid concurrent administration of live vaccines with ETICOVO. Patients, if possible, should be brought up to date with all immunizations prior to initiating ETICOVO. In patients with exposure to varicella virus, temporarily discontinue ETICOVO and consider prophylactic treatment with Varicella Zoster Immune Globulin.

AUTOIMMUNITY

Autoantibodies may develop with ETICOVO, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ETICOVO. Stop ETICOVO if findings suggestive of lupus-like syndrome or autoimmune hepatitis develop and evaluate the patient.

NOT RECOMMENDED FOR GRANULOMATOSIS WITH POLYANGIITIS PATIENTS ON IMMUNOSUPPRESSANTS

The use of ETICOVO in patients with granulomatosis with polyangiitis receiving immunosuppressive agents (e.g., cyclophosphamide) is not recommended.

INCREASED MORTALITY IN PATIENTS WITH MODERATE TO SEVERE ALCOHOLIC HEPATITIS

Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ETICOVO in patients with moderate to severe alcoholic hepatitis.

DRUG INTERACTIONS

The use of ETICOVO in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ETICOVO and anakinra is not recommended. Hypoglycemia has been reported following initiation of ETICOVO therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.

ADVERSE REACTIONS

The most commonly reported adverse reactions in RA clinical trials were injection site reaction and infection. In clinical trials of all other adult indications, adverse reactions were similar to those reported in RA clinical trials.

In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population.

INDICATIONS

ETICOVO (etanercept-ykro) is a TNF blocker indicated for:

Rheumatoid Arthritis: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA).

Polyarticular Juvenile Idiopathic Arthritis (pJIA): Reducing signs and symptoms of moderately to severely active pJIA in patients 2 years of age and older.

Psoriatic Arthritis: Reducing signs and symptoms, inhibiting structural damage progression, and improving physical function in adults (alone or with methotrexate).

Ankylosing Spondylitis: Reducing signs and symptoms in patients with active disease.

Plaque Psoriasis: Treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Please read the Full Prescribing Information, including BOXED WARNINGS and Medication Guide.

About Teva

Teva Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute the agreement with Samsung Bioepis and to successfully commercialize infliximab-abda and ETICOVO (etanercept-ykro) in the U.S.; our ability to successfully execute our additional collaborations with Samsung Bioepis; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and other factors discussed in our Quarterly Reports on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ending December 31, 2025, including in the section captioned "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings (KRX: 0126Z0), Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

_______________

1 Remicade is a trademark of Janssen Biotech, Inc., a Johnson & Johnson company

2 Enbrel is a trademark of Immunex Corporation, an Amgen subsidiary.

3 Soliris is a trademark of Alexion Pharmaceuticals, Inc.

4 Fasenra is a trademark of AstraZeneca AB.

5 Ilaris is a trademark of Novartis AG.

6 infliximab-abda - FDA-approved biosimilar to Remicade (infliximab): https://purplebooksearch.fda.gov/index.cfm?event=productdetails&blaNo=761054

7 etanercept-ykro - FDA-approved biosimilar to Enbrel (etanercept): https://purplebooksearch.fda.gov/index.cfm?event=productdetails&blaNo=761066

Bridge Data Centres Appoints New Co-Chief Executive Officer

Tue, 03 Nov 2026 21:45:00 +0700

Source: Bridge Data Centres

Mr Drew Chen's appointment as Co-CEO strengthens BDC's leadership team as the Company surpasses one gigawatt of capacity in 2026 and accelerates its growth across Asia Pacific.

SINGAPORE - Media OutReach Newswire - 3 November 2026 - Bridge Data Centres (BDC) is pleased to announce the appointment of Mr Drew Chen as Co-Chief Executive Officer (Co-CEO), effective 1 November 2026. He will work alongside Mr Eric Fan, BDC's Co-CEO, as a key member of the leadership team to accelerate the Company's growth across Asia Pacific and beyond.

Mr Chen brings over 20 years of private equity experience, with a focus on the telecommunications, media, technology, and business services sectors. He previously served as a Senior Partner at Bain Capital and was a founding member of the firm's Asia Pacific private equity team.

Prior to Bain Capital, Mr Chen worked at Bain & Company. He holds a bachelor's degree in economics from Harvard University and an MBA from Harvard Business School.

Mr Eric Fan, Co-CEO of Bridge Data Centres, said, "On behalf of Bridge Data Centres, we would like to welcome Drew. His appointment strengthens our leadership team at an important point in BDC's growth, as we surpass one gigawatt of capacity in 2026. Drew's experience and deep domain knowledge of the data centre sector will support our strategy as we scale BDC into a multi-gigawatt digital infrastructure platform in the coming years."

Mr Drew Chen, Co-CEO of Bridge Data Centres, said, "The Asia Pacific data centre sector is at inflection point for growth, fuelled by surging cloud adoption and the rapid expansion of AI workloads. BDC is well positioned to capture this opportunity, backed by our world class engineering and design team, longstanding partnerships with global clients, and a decade of experience developing and operating next-generation digital infrastructure. I am excited to partner with Eric and the leadership team to scale BDC's footprint across Asia Pacific and support our customers' ambitious growth plans."

Mr Jonathan Zhu, Partner and Chair of China at Bain Capital, said, "Drew possesses deep expertise in the digital infrastructure space and an intimate knowledge of BDC's business, having played a pivotal role in the buildout of BDC and its sister company ChinData. We are delighted that, as the Co-CEO, Drew will continue to bring strategic foresight and robust business building capabilities to BDC. Together, he and Eric are well positioned to lead BDC through its next chapter of growth."

Headquartered in Singapore, BDC is one of Asia Pacific's top three next-generation digital infrastructure platforms by live capacity, with a presence across Malaysia, Thailand, Singapore, and India.

About Bridge Data Centres

Bridge Data Centres (BDC) is a Singapore headquartered digital infrastructure platform delivering next-generation data centres across Asia Pacific and beyond.

Backed by Bain Capital, BDC operates in Malaysia, Thailand, India, and other high-growth markets, with an ambition to scale into a multi-gigawatt digital infrastructure platform in the near future.

The issuer is solely responsible for the content of this announcement.

Hashtags: #BridgeDataCentres

https://www.bridgedatacentres.com/

https://th.linkedin.com/company/bridgedc

YYForce Menyoroti Aset Bersih yang Dilaporkan Sebesar US$21,9 Juta serta Menguraikan Prioritas Robotika Komersial dan Platform AI

Tue, 03 Nov 2026 21:31:00 +0700

YYForce menyajikan nilai buku ekuitas yang telah dilaporkan beserta kapitalisasi pasarnya untuk memberikan konteks tambahan terkait rencana pertumbuhan perusahaan kepada rencana pertumbuhan perusahaan

SINGAPURA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- YYForce Inc. (Nasdaq: YFOR) ("YYForce" atau "Perusahaan"), penyedia solusi tenaga kerja dan layanan pengelolaan fasilitas terpadu berbasis teknologi, hari ini menyoroti aset bersih perusahaan yang dilaporkan sebesar sekitar US$21,9 juta, dibandingkan dengan estimasi kapitalisasi pasar sekitar US$2,1 juta per 30 Oktober 2026, serta menguraikan prioritas perusahaan di bidang robotika komersial dan AI.

YYForce menyampaikan informasi ini untuk membantu investor mengevaluasi basis aset yang dilaporkan perusahaan beserta hasil operasional, likuiditas, serta strateginya di bidang platform tenaga kerja, pengelolaan fasilitas terpadu, dan robotika layanan.

Posisi keuangan yang dilaporkan dan perbandingan valuasi

Sebagaimana dilaporkan dalam Formulir 6-K Perusahaan yang telah disampaikan pada 25 September 2026, neraca konsolidasian YYForce per 30 Juni 2026 menunjukkan angka-angka berikut.

Pos neraca	Jumlah yang dilaporkan
Total aset	Sekitar US$38 juta
Ekuitas yang dapat diatribusikan kepada pemegang saham YYForce (aset bersih)	Sekitar US$21,9 juta

Per 30 Oktober 2026, estimasi kapitalisasi pasar ekuitas perusahaan mencapai sekitar US$2,1 juta, setara dengan sekitar 9,6% dari ekuitas yang dilaporkan dan dapat diatribusikan kepada pemegang saham YYForce. Angka tersebut menunjukkan diskon sekitar 90,4% terhadap nilai buku ekuitas yang dilaporkan. Informasi ini menggunakan angka yang telah dibulatkan serta mencerminkan data keuangan dan data pasar dari tanggal yang berbeda.

Nilai buku ekuitas tidak mencerminkan kas yang penggunaannya tidak dibatasi, aset bersih berwujud, hasil likuidasi, atau estimasi nilai intrinsik. Nilai tercatat aset bergantung pada estimasi akuntansi dan penilaian penurunan nilai. Investor perlu mempertimbangkan laporan keuangan secara keseluruhan, termasuk liabilitas, hasil operasional, arus kas, dan pengungkapan selanjutnya.

Komentar manajemen

"Kami meyakini bahwa selisih antara nilai buku ekuitas yang kami laporkan dan kapitalisasi pasar perusahaan di pasar publik patut mendapat perhatian investor," ujar Mike Fu, Chief Executive Officer YYForce. "Tanggung jawab kami adalah menyediakan informasi keuangan yang jelas dan melaksanakan strategi komersial kami. Kami tetap berfokus pada penyediaan layanan bagi pelanggan, alokasi modal yang disiplin, serta pengembangan bisnis solusi tenaga kerja, pengelolaan fasilitas, dan robotika layanan kami."

"Kami akan mengevaluasi setiap investasi berdasarkan permintaan pelanggan, likuiditas yang tersedia, kebutuhan modal, dan imbal hasil yang diharapkan," tambah Fu.

Prioritas pertumbuhan strategis

Ekspansi robotika komersial. Mengupayakan penerapan robotika layanan dan integrasinya ke dalam alur kerja sektor perhotelan dan perusahaan, dengan memperhatikan kebutuhan pelanggan, biaya penerapan, serta dukungan berkelanjutan.

Platform pengelolaan fasilitas dan tenaga kerja yang didukung AI. Mengembangkan kemampuan platform digital dan mendorong penerapannya di perusahaan untuk mendukung koordinasi tenaga kerja, pelaksanaan shift kerja, dan operasional fasilitas.

Disiplin pengelolaan modal dan transparansi pasar. Mengevaluasi penerapan komersial berdasarkan permintaan pelanggan, kebutuhan modal, dan imbal hasil yang diharapkan. Selain itu, memberikan informasi terbaru yang jelas kepada pemegang saham mengenai perkembangan yang signifikan.

YYForce akan terus menilai kinerja operasional, kebutuhan pembiayaan, dan prioritas alokasi modalnya sesuai dengan perkembangan bisnisnya. Kemajuan komersial di masa mendatang tetap bergantung pada pelaksanaan operasional, tingkat adopsi oleh pelanggan, dan kondisi pasar yang lebih luas.

Tentang YYForce Inc.

YYForce Inc. (Nasdaq: YFOR) adalah perusahaan penyedia solusi tenaga kerja dan layanan pengelolaan fasilitas terpadu berbasis teknologi. Perusahaan tengah mengembangkan platform pengelolaan tenaga kerja dan kapabilitas robotika berteknologi AI untuk mendukung kegiatan operasional di lini depan, meningkatkan produktivitas, serta memenuhi kebutuhan pelanggan yang terus berkembang.

Untuk informasi lebih lanjut, kunjungi www.yyforce.ai.

Pernyataan Berwawasan ke Depan

Siaran pers ini memuat pernyataan berwawasan ke depan sebagaimana dimaksud dalam Pasal 27A Undang-Undang Sekuritas AS Tahun 1933, sebagaimana telah diubah, dan Pasal 21E Undang-Undang Perdagangan Sekuritas AS Tahun 1934, sebagaimana telah diubah. Pernyataan-pernyataan tersebut didasarkan pada ekspektasi dan asumsi Perusahaan saat ini, serta informasi yang tersedia bagi Perusahaan pada tanggal rilis siaran pers ini. Pernyataan berwawasan ke depan dapat dikenali melalui penggunaan kata-kata seperti "mungkin", "akan", "seharusnya", "memperkirakan", "mengantisipasi", "merencanakan", "bermaksud", "meyakini", "mengestimasi", "potensi", atau ungkapan serupa, maupun bentuk negatif dari istilah-istilah tersebut.

Pernyataan berwawasan ke depan dalam siaran pers ini termasuk, tetapi tidak terbatas pada, ekspektasi mengenai strategi, penerapan komersial, pengembangan platform, efisiensi operasional, alokasi modal, dan kinerja bisnis Perusahaan di masa mendatang. Data keuangan historis bukan merupakan pernyataan berwawasan ke depan. Nilai buku ekuitas yang dilaporkan bukan merupakan indikator harga yang mungkin berlaku dalam perdagangan saham perusahaan maupun jumlah yang mungkin diperoleh dari penjualan atau likuidasi.

Pernyataan berwawasan ke depan mengandung risiko dan ketidakpastian yang melekat, dan peristiwa di masa mendatang yang dibahas dalam siaran pers ini mungkin tidak terjadi. Peristiwa dan hasil aktual dapat berbeda secara signifikan serta bergantung pada risiko, ketidakpastian, asumsi mengenai Perusahaan, dan sejumlah faktor lainnya.

Untuk pembahasan lebih terperinci mengenai faktor-faktor risiko, silakan merujuk pada dokumen yang diserahkan Perusahaan kepada Komisi Sekuritas dan Bursa AS (SEC), termasuk bagian "Faktor Risiko" dalam laporan tahunan terbaru Perusahaan pada Formulir 20-F, sebagaimana diubah. YYForce tidak berkewajiban untuk memperbarui pernyataan ini kecuali sebagaimana diwajibkan oleh hukum yang berlaku.

Berakar pada Perpetua, EXEED Memperkenalkan Bahasa Desain Barunya: Kemewahan Masa Depan

Tue, 03 Nov 2026 21:28:00 +0700

SHANGHAI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Acara "Peluncuran Bahasa Desain Baru" berlangsung di Pusat Inovasi Teknologi Global Chery di Shanghai sebagai bagian dari EXEED International User Summit 2026. Mengusung tema "Kemewahan Masa Depan", acara tersebut memperkenalkan bahasa desain baru untuk seluruh lini kendaraan EXEED.

Penata Desain Merek, Christo Pavlidis, dan Kepala Desainer, Juan Manuel Diaz, memperkenalkan lima model kendaraan, yaitu ES GT, EX9, EX8, EX7, dan MPV Concept. Kelima model tersebut masing-masing menghadirkan interpretasi tersendiri atas konsep Kemewahan Masa Depan. Setiap model memenuhi ekspektasi pengguna yang terus berkembang terhadap kemewahan, performa, dan teknologi mutakhir.

Inti dari konsep Kemewahan Masa Depan adalah Perpetua, sebuah filosofi desain yang terinspirasi dari perubahan gelombang Samudra Atlantik mengikuti cahaya, pasang surut air laut, dan waktu. Filosofi ini diwujudkan dalam dua bentuk ekspresi. Air berwujud cair merepresentasikan kecepatan dan ketegangan pada model-model yang berorientasi sporty.

Sementara itu, permukaan dengan garis tegas dan bentuk pahatan yang terinspirasi dari es kutub padat menjadi dasar bagi model-model kendaraan mewah masa depan. Konsep sporty dan kemewahan bukanlah dua bahasa desain yang terpisah, melainkan dua ekspresi dari estetika yang sama. Dengan demikian, bahasa desain tersebut dapat diterapkan pada berbagai kategori kendaraan.

EX9 merupakan model pertama yang sepenuhnya mewujudkan bahasa desain ini di segmen kendaraan mewah. Jarak sumbu roda yang panjang, overhang depan yang pendek, dan bodi yang tegak menciptakan postur SUV unggulan yang mantap. Gagang pintu yang rata dengan permukaan bodi dan garis bahu yang menyambung tanpa putus membentuk siluet menyerupai pahatan. Desain ini menonjolkan proporsi, material, dan permainan cahaya dengan ornamen seminimal mungkin.

EX8 menonjolkan garis-garis horizontal dan menawarkan ruang kabin yang lapang bagi konsumen SUV premium yang bepergian bersama keluarga atau rombongan. Sementara itu, EX7 mengusung elemen desain EX9 dalam bentuk yang lebih sporty. MPV Concept mengeksplorasi bentuk-bentuk desain yang melampaui sedan dan SUV konvensional, sekaligus menunjukkan fleksibilitas konsep Kemewahan Masa Depan untuk berbagai kategori kendaraan.

ES GT mengekspresikan sisi yang lebih dinamis dari konsep Kemewahan Masa Depan. Sebagai crossover wagon pertama EXEED, bodinya yang rendah dan memanjang menciptakan kesan seolah-olah kendaraan sedang bergerak maju, bahkan saat diam. Di bagian interior, kokpit simetris dengan desain melengkung dilengkapi Sky Screen dan layar tengah yang melayang. Sementara itu, jok sport terintegrasi memberikan penopang samping aktif. Desain sportynya juga tercermin dalam pengalaman berkendara, menghadirkan DNA balap EXEED ke dalam kabin.

Setelah acara tersebut, tim desain mengadakan lokakarya bersama perwakilan pengguna dari berbagai negara. Masukan mereka akan membantu EXEED memahami kebutuhan pengguna dengan lebih baik. Dengan memanfaatkan teknologi parkir pintar SIVP, Texxeract, dan DNA balapnya, EXEED tengah membentuk visi baru tentang mobilitas di pasar global melalui desain, performa, dan teknologi mutakhir.

Global Pharmaceutical Company Commits to a Dual-Site Deal with AGC Biologics Exceeding EUR 0.5 Billion

Tue, 03 Nov 2026 18:55:00 +0700

Agreement builds on customer's long-term deal in new Yokohama facility for five commercial biologics programs, now allocating an additional six commercial programs to Copenhagen facility to consolidate high-volume, single-use biologics manufacturing with one global partner

Deal reflects a shared belief that site interoperability and dual submissions are key to unlocking the benefits of local manufacturing for a global supply

Running multiple sites as one integrated supply node lets both companies move production quickly between locations as needs change

COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- AGC Biologics has expanded its existing long-term manufacturing agreement with a global pharmaceutical company, adding a second supply node at the CDMO's Copenhagen facility. The expansion, which builds on the existing agreement anchored at AGC Biologics' Yokohama site, grows the deal's total value beyond EUR 0.5 billion.

The expanded deal calls for multi-product drug substance manufacturing across six biologics programs at AGC Biologics' Copenhagen site, encompassing process transfer, scale-up, validation, and commercial production. Products will launch and move across facilities with several dual regulatory submissions to optimize capacity, cost, and local manufacturing benefits, capturing levels of flexibility and supply chain robustness that could not be achieved with a single-site supply arrangement.

"This customer is building a more resilient, more flexible supply chain, and they've chosen to do that with us across two continents. This is exactly what we're well-positioned to offer to a market craving geographic flexibility and regionalization, while retaining global supply," said Alberto Santagostino, President and CEO of AGC Biologics. "We've built our single-use strategy around quality, capacity, and deep technical expertise so that when a partner is ready to localize and scale, we can meet them where they are. This deal takes inter-site flexibility to a larger scale, but it builds on our existing experience: two of our customers have already decided to co-launch their products from both our Seattle and Copenhagen facilities."

This agreement further cements AGC Biologics as a prominent global player in single-use bioreactor manufacturing, serving the large-scale mammalian single-use manufacturing needs of major pharmaceutical companies across regions. AGC Biologics maintains one of the largest global networks of single-use manufacturing capacity by volume in the industry, according to BDO's bioTRAK database.

By combining strong commercialization capabilities with a friendly and expert CDMO approach, AGC Biologics supports customers pursuing cross-site launches, geographic flexibility, and regionalized manufacturing strategies across its global network.

"For a customer to bring six additional programs to Copenhagen, after bringing five to Yokohama, tells you everything about the trust our team has earned across the network," said Tadashi Murano, President of AGC Life Science Company. "Our focus stays on building lasting and trust-based relationships with our pharmaceutical customers, like we have been doing for decades in AGC with our industrial partners across a wide range of industries including electronics and automotive."

Frequently Asked Questions (FAQs)

Why isn't the customer named in this announcement?

Consistent with standard practice in the biopharmaceutical industry, customer names are not disclosed without the customer's consent. AGC Biologics regularly enters into confidential manufacturing agreements to protect its customers' competitive and regulatory strategies.

Could this customer expand its manufacturing relationship with AGC Biologics further?

AGC Biologics operates GMP manufacturing sites across the U.S., Europe, and Asia, providing capacity for customers to expand into additional regions as their commercial manufacturing needs evolve.

What does AGC Biologics' Copenhagen site offer to large-scale developers?

Scientific teams at AGC Biologics' Copenhagen site have 25 years of expertise in drug substance development and GMP manufacturing. Customers using the site have received a total of over 50 commercial approvals from more than 20 regulatory agencies.

The Copenhagen site expansion in 2024 included 18,000 square meters distributed across manufacturing, quality control laboratories and technical and warehouse areas, including:

Eight 2,000-liter single-use bioreactor production lines

One 500-liter perfusion bioreactor

Two downstream purification lines

About AGC Biologics

AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells.

Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs eight facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com.

Arla Foods Ingredients and wheyco to exhibit together at Fi Europe under 'Growing Stronger Together' theme

Tue, 03 Nov 2026 18:51:00 +0700

FRANKFURT, Germany, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Arla Foods Ingredients and wheyco, DMK Group's whey business, are to exhibit together at a trade event for the first time since the merger of their parent companies.

On 1st June, Arla Foods and DMK Group came together to form Europe's largest dairy cooperative. At Fi Europe (17th-19th November in Frankfurt), Arla Foods Ingredients, a subsidiary of Arla Foods, will demonstrate how the merger has created a stronger ingredients business.

The DMK Group and Arla Foods Ingredients stands will be located opposite one another, both carrying the message 'Growing Stronger Together', with DMK's subsidiary wheyco represented on the Arla Foods Ingredients stand.

Anne Widart, Vice President, Commercial, at Arla Foods Ingredients said: "One of the many benefits of the merger has been the creation of an ingredients powerhouse. It has unlocked new synergies and opportunities, allowing us to build something even better for the future. Fi Europe is the perfect platform to demonstrate our shared ambitions."

Earlier this year, Arla Foods Ingredients debuted its 'Targeted GLP-1 Companion Nutrition' concept, demonstrating how nutrient-dense products can meet the needs of GLP-1 users. At Fi Europe, it will showcase new applications, including a spoonable yogurt, a drinking yogurt, a fermented high-protein shot and a high-protein water-based shot.

The 'Unlock Permeate' concept will demonstrate how Arla Foods Ingredients' Variolac can improve cost-effectiveness and sensory properties in dairy, bakery and confectionery applications. Produced through nanofiltration, the whey permeate ingredient offers a mild milky taste, high cost efficiency and high content of calcium, magnesium and potassium.

Visitors can also sample new active nutrition solutions, including protein shakes, protein waters and the AirBar - an aerated milk protein bar with a light texture offering a new sensory experience in the protein bar category.

Anne Widart added: "These concepts typify Arla Foods Ingredients' commitment to innovation, from GLP-1 companion nutrition and active nutrition to improving taste and cost efficiency with whey permeate. With our expertise and capabilities further enhanced by the merger, we can deliver even greater value to our customers."

Meanwhile, DMK Industry will showcase its fat-filled ingredients, TOPPICS, FATTICS and BATTICS, and Sweetened Condensed Milk portfolios through four indulgent concepts: cupcakes with an aerated topping, chocolate caramel cookies, chocolate espresso fudge and a Cafe Bomb?n.

Arla Foods Ingredients will exhibit at Stand #30J94, opposite DMK Group at #30K94.

Philips delivers strong order intake growth, comparable sales growth and strong margin expansion in Q3; 2026 outlook reiterated

Tue, 03 Nov 2026 18:44:00 +0700

November 3, 2026

Q3 2026 Group performance

Comparable order intake increased by 8%, driven by strong Diagnosis & Treatment

Group sales of EUR 4.4 billion, reflecting 3% comparable sales growth

Income from operations of EUR 165 million

Adjusted EBITA margin increased 70 basis points to 13.0%, with expansion across all business segments

Operating cash flow of EUR 544 million; free cash flow of EUR 384 million

Respironics reached agreement in principle with the US Department of Justice

Philips reiterates its full-year 2026 outlook

Roy Jakobs, CEO of Royal Philips:

"We delivered an excellent 8% comparable order intake, led by broad-based order momentum in Diagnosis & Treatment, and 3% comparable sales growth in the third quarter, led by Personal Health and Connected Care. Our innovations and productivity measures drove continued margin expansion across all business segments.

We are executing our plan to accelerate profitable growth, with strong customer demand for our latest AI-enabled innovations, including our new CT platforms Verida and Rembra, our latest ultrasound system Alturion, and our HealthSuite Imaging cloud solution. These innovations demonstrate how our platforms bring together hardware, software, data and AI to create greater value for customers. We look forward to showcasing our next innovations at RSNA later this month.

We continue to make progress in resolving the consequences of the Sleep & Respiratory Care recall. The Respironics agreement in principle with the US Department of Justice marks an important step in this process.

Our year-to-date results, together with our strong order book, give us confidence in delivering our full-year outlook and achieving our medium-term ambitions. As we move forward in collaboration with customers, our hardworking teams around the world are focused on putting quality at the heart of our operations as we deliver better care for more people."

Group and segment performance

Comparable order intake grew 8%, driven by strong growth in Diagnosis & Treatment. Comparable sales increased by 3%, driven by Personal Health and Connected Care.

Adjusted EBITA margin increased 70 basis points to 13.0%, mainly driven by higher sales, higher gross margin and productivity measures, partly offset by cost inflation. Net cash flows from operating activities increased to EUR 544 million, mainly driven by higher cash earnings and lower working capital outflows. Free cash flow increased to EUR 384 million.

Diagnosis & Treatment comparable sales growth was flat. Growth in Image Guided Therapy was offset by a decline in Precision Diagnosis, mainly due to phasing of Ultrasound sales and lower sales in China as previously communicated at Q2. Adjusted EBITA margin increased 50 basis points to 12.3%, mainly driven by gross margin from innovation and productivity measures, partly offset by cost inflation.

Connected Care comparable sales increased by 5%, driven by growth in all businesses. Adjusted EBITA margin increased 190 basis points to 13.3%, mainly driven by higher sales, higher gross margin, and productivity measures, partly offset by cost inflation.

Personal Health comparable sales increased by 8%. Adjusted EBITA margin increased 60 basis points to 17.7%, mainly driven by higher sales and productivity measures, partly offset by advertising and promotion spend.

Innovation highlights

Philips is accelerating innovation in image-guided therapy. In the Netherlands, Philips is investing EUR 50 million in AI, robotics and advanced imaging, alongside over EUR 100 million from the Dutch government and a further EUR 150 million in private financing by Invest-NL and institutional investors, including pension funds. In the US, an ARPA-H award of up to USD 34 million will support AI-enabled robotic stroke care on the Azurion platform.

The Philips-coordinated European COMBINE-CT project advanced into clinical validation, launching five clinical studies to evaluate an integrated care pathway enabled by AI-powered CT and Spectral CT imaging solutions.

Philips extended its monitoring partnership with one of the largest US health systems through 2034. The national agreement covers equipment and services, expands the use of Philips' Capsule platform, and supports future technology needs.

Ontario Health in Canada selected the Philips Enterprise Imaging Vendor Neutral Archive to modernize province-wide imaging infrastructure and connect patient information across care settings. This Vendor Neutral Archive will support the sharing of more than 20 million imaging studies annually across more than 150 hospitals and 50 imaging clinics, helping enable a holistic patient view and more timely access to care.

Philips is supporting major healthcare programs in Latin America, including the modernization of 50 public hospitals in Venezuela, and an expanded partnership with Mexico's largest public healthcare institution, IMSS. The projects bring advanced imaging, image-guided therapy and monitoring technologies to more patients, expanding access to diagnostic, cardiac, neurological and stroke care.

Philips signed a long-term strategic partnership with Asia Medical Group to advance integrated cardiovascular care in China. The partnership will focus on clinical care, training, research and international collaboration, combining Philips' diagnostic imaging and image-guided therapy capabilities with Asia Medical Group's cardiovascular expertise.

Personal Health launched innovations across oral care, beauty and mother and child care. These include the AI-powered Sonicare DiamondClean 9900 Prestige, the first at-home IPL with real-time guidance Lumea 9900 Pro, and Philips Avent's first fully wearable Natural Care breast pump, bringing more personalized and premium solutions to consumers.

Productivity

Disciplined cost management and productivity initiatives delivered EUR 170 million in net savings in the quarter and EUR 427 million year-to-date. The company remains on track to deliver EUR 1.5 billion in savings under its 2026-2028 productivity program.

Progress on Respironics-related legal proceedings

Philips Respironics reached an agreement in principle with the US Department of Justice (DOJ) to resolve the previously disclosed criminal and civil investigations related to the Respironics recall. As a result, Philips recorded a provision of EUR 288 million in the third quarter of 2026. The settlement is subject to finalization of the relevant documentation; payment is expected in the first quarter of 2027.

Also in the third quarter, the Enterprise Chamber of the Amsterdam Court of Appeal denied requests from certain investors for an investigation into the affairs of Philips in connection with the Respironics recall.

Outlook

Philips reiterates its full-year 2026 outlook:

Comparable sales growth: 3%-4.5%

Adjusted EBITA margin: 13.5%-14.0%, including a US tariff refund benefit of approximately 1%

Free cash flow: EUR 1.5-1.7 billion, including a net US tariff refund benefit of approximately EUR 200 million

Within the context of an uncertain macro-environment, Philips' 2026 outlook includes currently known tariffs and assumes payment of the US Department of Justice settlement in the first quarter of 2027. The outlook excludes other ongoing Philips Respironics-related proceedings, including the investigation by the US State Attorneys General.

Capital allocation

In the third quarter, Philips issued EUR 650 million fixed rate notes due 2034 (the "Notes") under its European Medium Term Note program. The Notes are the healthcare industry's first EU Green Bond under the new European Green Bond Standard and were 2.7 times oversubscribed, reflecting strong investor demand. An amount equivalent to the gross proceeds will be used to finance taxonomy-aligned economic activities as referred to in the Philips European Green Bond Factsheet, supporting Philips in delivering on its 2030 Impact Ambitions. See here for more information on Philips' current debt structure.

Further information: conference call, video webcast and website

Roy Jakobs, CEO, and Charlotte Hanneman, CFO, will host a conference call for investors and analysts at 10:00 am CET on November 3, 2026, to discuss the results. A live webcast will be available on the Philips Investor Relations webpage and can be accessed here. A replay and related materials, including additional information on the outlook and forward-looking statements, will be available on the Philips Investor Relations webpage.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,900 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements and other information

Forward-looking statements

This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future Adjusted EBITA*, future restructuring and acquisition-related charges and other costs, future developments in Philips' organic business and the completion of acquisitions and divestments. Forward looking statements can be identified generally as those containing words such as "anticipates", "assumes", "believes", "estimates", "expects", "should", "will", "will likely result", "forecast", "outlook", "projects", "may" or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

These factors include, but are not limited to, macro-economic and geopolitical changes - including the war in Ukraine and ongoing tensions in the Middle East - as well as measures such as enacted and proposed tariffs and trade actions introduced in response to rising global tensions; Philips' ability to keep pace with the changing health technology environment; Philips' ability to gain leadership in artificial intelligence and health informatics in response to developments in the health technology industry; integration of acquisitions and their delivery on business plans and value creation expectations; ability to meet expectations with respect to ESG-related matters; securing and maintaining Philips' intellectual property rights, and unauthorized use of third-party intellectual property rights; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations; the resilience of our supply chain; challenges in simplifying our organization and our ways of working; attracting and retaining personnel; breach of cybersecurity; challenges in driving operational excellence and speed in bringing innovations to market; treasury and financing risks; tax risks; reliability of internal controls; compliance with regulations and standards involving quality, product safety, (cyber) security and artificial intelligence; and compliance with business conduct rules and regulations including privacy, existing and upcoming ESG disclosure and due diligence requirements. As a result, Philips' actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Further information chapter included in the Annual Report 2025.

Third-party market share data

Statements regarding market share contained in this document, including those regarding Philips' competitive position, are based on outside sources such as specialized research institutes, as well as industry and dealer panels, in combination with management estimates. Where information is not yet available to Philips, market share statements may also be based on estimates and projections prepared by management and/or based on outside sources of information. Management's estimates of rankings are based on order intake or sales, depending on the business.

Market Abuse Regulation

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Use of non-IFRS information

In presenting and discussing the Philips Group's financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2025.

Presentation

All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2025. Certain prior year balances have been reclassified to conform to the current period presentation.